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Abstract
Cancer testis genes are common targets for the development of
immunotherapy for cancer treatment. Ovarian cancer is one of the leading causes of
death in women cancer patients. Cancer testis genes play a role in tumorigenesis,
but it is not clear how these genes are activated. This study utilized differential
expression analysis between The Cancer Genome Atlas (TCGA) ovarian cancer data,
Genotype-Tissue Expression (GTEx) non-cancerous ovary and testis data, and cell
line data to identify a list of cancer testis genes that have a novel expression profile.
To identify ovarian cancer testis genes, we obtained normal ovary tissue data and
normal testis germline data from GTEx and cancerous ovarian tissue samples from
TCGA. We defined a cancer testis gene if it matched an expression pattern of being
differentially expressed in cancer and germline samples, as compared to normal
tissue samples. The analysis discovered 4,578 genes that satisfied the condition of
cancer testis genes. To facilitate downstream mechanistic analyses aimed to evaluate
how these genes are misregulated, we identified 87 genes that satisfied the
conditions in common ovarian cancer cell lines, as compared to human foreskin
fibroblast normal cells. There were 28 genes found in common between both these
lists that met our target expression profile whose misexpression will be evaluated in
future studies.

x

1 Introduction
This experiment aims to further investigate how cancer testis (CT) genes are
misregulated in cancer. A key feature of oncogenesis is the switch of a cell from its
differentiated type to a germline-like state, a process where CT genes are known to
be involved in [1]. Previous analyses using presence/absence methods reveal a
stochastic model by which germline genes are activated in some cancers [1]. We
hypothesize that differential analysis will reveal novel information to the CT genes
involved in this process. In addition to testing tissue level data, we are testing our
novel pipeline using cell line data from the BJ/HFF, SKOV3, and OVCAR3 lines as part
of the filtering process for CT genes. SKOV3 and OVCAR3 are known models for
ovarian cancer study, making our analysis consistent with other analyses.

1.1 Cancer testis genes
Cancer testis (CT) genes were first discovered in 1991 when van der Bruggen
noticed that cytolytic T lymphocytes were able to target the tumor cells [2]. Since
then, it has been noted that up to 40% of cancers express CT genes [3]. CT genes
are designated as genes that are expressed in testis and cancerous cells but are not
expressed in normal cells [4]. As of 2017, there have been nearly 800 CT genes
identified [5,6]. These genes have been classified into two groups: CT-X and non-x
CT genes, standing for CT genes found on the X chromosome and CT genes found on
autosomal chromosomes [5,7]. Of the nearly 900 genes on the X chromosome, 10%
of them have been designated as CT genes [5].
Despite the identification of many CT genes, the function of many is unknown
[8]. The difficulty arises from many factors but primarily that CT genes are not well
1

conserved or that they lack known motifs to identify function. With this being said,
CT genes have been proven to contribute to tumorigenesis in Drosophila
melanogaster [9]. Many studies have shown that individual CT genes are oncogenic
in certain cancers [10 – 52]. Knowing that there are CT genes that play a role in
tumorigenesis, the discovery of novel CT genes could provide a breakthrough in
immunotherapy development.

1.2 Cancer testis antigens and immunotherapy
While there have been numerous CT genes identified, not every CT gene is
useful in immunotherapy. A CT gene is useful in immunotherapy if that gene encodes
for an antigen that is expressed by a tumor cell [3]. If a cancer testis antigen (CTA)
is expressed by the tumor cell, a vaccine or genetically engineered cytolytic-T cell
could be used to treat the cancer [2, 7, 53 – 56]. Without an antigen to target, it is
very difficult to perform treatment specific to the cancerous cells, which is why when
a CT gene is discovered, it is imperative that the gene is studied to determine if it
encodes for an antigen.
There have been a couple of molecular methods that have shown how CT
antigens become expressed in cancer cells. Among these are the DNA
hypomethylation of promoters, and histone marker modification and modulation that
results in the loss of repressive histone marks and/or gain of activating histone
marks [57]. Specifically for DNA hypomethylation, it is not the methylation of the
CTA promoter that occurs, but rather the inhibition of a promoter of a regulatory
element that suppresses the CTA gene. It is not known which regulatory elements
are responsible for these gene suppressions and is likely to be specific to each CTA
gene.
2

1.3 Ovarian cancer and CT genes
As of 2022, ovarian cancer is the fifth leading cause of cancer deaths in women
and is the most lethal cancer in women [58]. It is estimated that nearly 20,000 new
women will be diagnosed with ovarian cancer in 2022, of which 12,000 are expected
to die. Ovarian cancer is defined as a group of tumors that grow in the ovary but are
not necessarily originated in the ovary [59]. Nearly 90% of all ovarian cancer
diagnoses are epithelial ovarian cancers, which can be subdivided into five
histological types: high-grade serous, low-grade serous, endometrioid, clear cell
carcinoma, and mucinous carcinomas. Cancer testis genes are abundantly found in
various ovarian cancer types, with most of them being expressed in epithelial ovarian
cancer [60]. Xie et al identified 38 CT genes to be expressed in ovarian cancer. A
second study elaborated to indicate that in ovarian cancer the CT genes MAGEB1,
MAGEB2, GAGE1, NY-ESO1 have an increased expression compared to other cancer
types while the MAGEA4, GAGE3, GAGE4, XAGE3, SSX2, SCP1, and PRAME1 genes
saw decreased expression [61]. While the number of ovarian cancer diagnoses are
declining over the years, any new revelations in treatment targets is welcome to
attempt to increase survivability.

1.4 New resources available
With the advancement of next generation sequencing technology, the need for
publicly available data has become paramount to advance the field in terms of
accessibility and reproducibility. The Cancer Genome Atlas (TCGA) has emerged as a
public source for genomic, epigenomic, transcriptomic, and proteomic data for
20,000 primary cancer and matched normal samples of 33 cancer types [62].
Similarly, the Genotype-Tissue Expression (GTEx) project is an ongoing effort to
3

build a public resource of tissue-specific gene expression patterns [63]. It is a
collection of 54 non-diseased tissue sites from almost 1000 individuals of various
molecular assays. Both resources were founded on the principal of creating publicly
available data so that researchers could pursue their interests with data that has
already been collected.
There have been many publications that utilize TCGA and GTEx for their sample
gathering, including genome-wide association studies and single cancer analysis [5,
6, 60, 64]. For two of these papers, da Silva 2017 and Wang 2016, TCGA and GTEx
data were used to identify cancer testis genes. These are our basis for which we
developed the pipeline to pursue our study.

1.5 Differential analysis technique
In this study, differential expression analysis of TCGA and GTEx data will be
used to detect CT genes, primarily utilizing the DESeq2 R package [65]. As with
previously mentioned genome-wide identification studies [4, 5, 6], we will be using
the DESeq2 and R to perform a large data sample analysis of ovarian cancer, ovarian
normal, and testis normal genomic data to identify CT genes. In addition, our study
will be intersecting the CT genes discovered with a list of genes obtained from
differential expression analysis of three cell lines: BJ/HFF, SKOV3, and OVCAR3.
The three cell lines are being utilized to identify genes that are highly expressed
in SKOV3 and OVCAR3 but not in the BJ/HFF line. BJ/HFF is being used as a control
for normal cell gene expression [66], SKOV3 as a low-grade serous/non-serous
epithelial line [59, 67], and OVCAR3 as a high-grade serous line [59, 68]. Each cell
line will be compared to each other, and genes will be selected based on the criteria
of taking genes that are more highly expressed in SKOV3 in the SKOV3-BJ/HFF
4

comparison, in OVCAR3 in the OVCAR3-BJ/HFF comparison, and OVCAR3 in the
SKOV3-OVCAR3 comparison. The reasoning for this selection is based on the findings
of Hallas-Potts et al in 2019 where they stated that the OVCAR3 line is clinically more
aggressive than the SKOV3 line [59]. We hypothesize that the more aggressive
cancer cell line will have a higher expression level of CT genes compared to the less
aggressive cancer cell line.
Once the CT genes have been identified and the cell line genes exhibiting the
described expression pattern, the lists will be intersected to determine the CT genes
that also exhibit the desired expression pattern. Together, this analysis will reveal
what CT genes are misexpressed in ovarian cancer cell line models, which will enable
future studies into what drives the misexpression of these genes.

5

Figure 1-1 Pipeline of analysis
Depiction of the pipeline utilized for the generation of the final gene list. The right side
depicts the process of the differential expression analysis of the ovary and testis data for the
identification of the CT genes. The left pathway depicts the process to convert the raw reads for
the three cell lines (BJ/HFF, SKOV3, OVCAR3) to the count data that was used in the differential
expression analysis.

6

1.6 Goals and hypotheses
The goal of this study is to utilize a novel bioinformatic pipeline to discover new
CT genes for ovarian cancer. While this study will not investigate further whether the
discovered CT genes produce antigens, the hypothesis is that we will obtain a set of
genes matching are combined expression pattern. The discovery of a novel set of
genes will provide the scientific community with possible genes to pursue to be
analyzed as potential immunotherapy targets, as well as additional genomic data
that could aid in the early detection of ovarian cancer development.

7

2 Materials and Methods
2.1 Data utilized
For the CT gene identification analysis, 170 samples of normal ovary data
from GTEx were utilized (Appendix A.1), 451 samples of ovary cancer data from
TCGA (Appendix A.2), and 351 samples of normal testis data from GTEx (Appendix
A.3).
The materials used for the cell line analysis include 3 samples of SKOV3 cell line
data and 3 samples of OVCAR3 cell line data from GSE134375 in GEO [68]. The
replicates for the SKOV3 lines were SRR9694244, SRR9694245, and SRR9694246.
The replicates for the OVCAR3 line were SRR96942450, SRR9694251, and
SRR9694252. The data for the BJ/HFF data was accessed from GEO with accession
number GSE117808. It should be noted that the contributors of the data were
Hemmerich P, Marthandan S, Huhne R, Groth M, and Platzer M in 2018, but there is
no citation given for the data. The samples used were SRR7513003, SRR7513004,
and SRR7513005. These data were RNAseq data and needed to be converted to
HTSEQ data. This was done using the Ubuntu command line and in a Bioconda
environment. The data files were downloaded and trimmed using the fastp command
package [69]. The quality of each trimmed sample was assessed by running the
fastqc command package[70]. The trimmed reads were mapped to the
Gencode_GRch38.p13 reference genome using the STAR package[71]. The mapping
files were then counted using the htseq-count command to generate the HTSEQ data
files [72].

8

2.2 Differential expression analysis of the ovarian and testis
tissue
The tissue sample data for the testis and ovaries were compared using the
DESeq2 R package in a similar fashion to the previous section [73]. First the GTEx
ovary data was compared to the GTEx testis data to establish a list of genes that
were up-regulated in the testis compared to the ovary using a cut-off of a log2 score
greater than 1. Next, the TCGA ovary data was compared to the GTEx ovary data to
obtain a list of genes up-regulated in the cancerous ovary line compared to the
normal line. The gene names of both sets were altered to remove gene identification
data of different variations of the same genes. This was done to allow expression
data of the same genes but different mutations to be overlapped. The two gene list
datasets had their counts extracted from their sources and were compared on a
differential expression basis to obtain a list of genes that met the criteria of being
up-regulated in testis and cancerous ovarian lines compared to the normal ovarian
tissue.

2.3 Differential expression analysis of ovarian cancer
cell lines
The HTSEQ count files for the BJ/HFF, SKOV3, and OVCAR3 cell lines were
analyzed for differential expression between the tissue samples using the DESeq2 R
package. The control group used was the BJ/HFF cell line data since this cell line is
not cancerous. Three analysis were conducted: one comparing the SKOV3 line to the
BJ/HFF line, OVCAR3 line compared to BJ/HFF line, and the OVCAR3 line compared to
the SKOV3 line. The results of the DESeq runs were extracted and the genes that
9

were differentially expressed by a log2 fold of 2 or greater were recorded. For the
BJ/HFF to SKOV3 comparison the genes expressed higher in SKOV3 were recorded,
For BJ/HFF and OVCAR3, the higher OVCAR3 genes expressed were recorded.
Likewise, the OVCAR3 genes that were more highly differentially expressed
compared to the SKOV3 genes were recorded. The intersection of the three gene
sets were recorded to obtain a list of genes that were up-regulated in SKOV3 against
BJ/HFF, up-regulated in OVCAR3 against BJ/HFF, and up-regulated in OVCAR3
compared to SKOV3.

2.4 Obtaining a list of CT genes
After both gene lists from the previous differential analysis were obtained, the
intersection of the two gene lists was taken to create a final gene list that contained
the CT genes in the ovarian samples that also had the expression pattern desired
from the OVCAR3, SKOV3, and BJ/HFF analysis.

10

3 Results
3.1 CT gene analysis pipeline
We first performed a principle component analysis (PCA) of the testis, normal
ovary, and cancerous ovary tissues (Figure 3-1). This analysis confirmed the quality
of the data sets. Our analysis indicates that the data is of sufficient quality to
continue with the rest of the pipeline without worrying about poor quality data
biasing the analysis.
The first differential expression analysis was performed on the testis tissue and
normal ovary tissue GTEx data. We plotted the -log10 p-adjusted values against the
log2 fold change of the results of this analysis (Figure 3-2). There were 16,807 genes
up-regulated with a log2 > 2 in the testis compared to the normal ovary tissues, as
indicated by the teal dots. The quality of the analysis was further assessed with an
MA plot to compare the log2 fold change of the samples to their base mean reads
(Figure 3-3). The overall distribution confirmed the results in Figure 3-2 and
indicated a clear distinction of the up-regulated genes in the testis. With the quality
of the analysis confirmed, the 16,807 up-regulated testis genes were selected and
advanced for further analysis.
To determine the genes up-regulated in the cancerous ovarian cells, ovary
tumor samples were compared to the normal ovary tissue samples using differential
expression analysis. The -log10 p-adjusted values were plotted against the log2 fold
change values of each gene (Figure 3-4). There were 11,850 genes found to be upregulated by a log2 fold factor > 2, depicted on Figure 3-4 as the purple dots. As
done previously, an MA plot of the results was created to determine the quality and
11

confidence in the gene expressions (Figure 3-5). The distribution along the y-axis
indicated that the genes expressed had a high confidence interval travelling up the
side. The 11,580 genes were selected and advanced to the next analysis.
The final step of the analysis was identifying the genes in common that were up
in the testis and the cancerous ovary tissues (Figure 3-6). The 16,807 up-regulated
testis genes were intersected with the 11,580 up-regulated tumor genes. A total of
5,478 genes are shared between the two groups, indicated in the purple region. We
defined these genes as ovarian CT genes, which were advanced to the next step of
the analysis.

12

Figure 3-2 PCA plot of testis and ovary data
This figure depicts the variance between the tissue data for normal ovary (red), normal
testis (green), and cancerous ovary (blue).
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Figure 3-3 Volcano plot of testis tissue vs ovary tissue
This figure depicts the -log10 adjusted p-value score plotted against the log2 fold change in
expression pattern between the testis tissue (teal) and the normal ovary tissue (orange). The grey
dots show the genes that were not statistically differentially expressed by a factor of 2 on the log 2
fold change scale.
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Figure 3-4 MA plot of testis tissue vs normal ovary tissue
This figure shows the gene expressions’ log2 fold change plotted against the base mean
counts of the data sets for the testis against ovary tissues. The orange dots represent the genes
that were up--regulated in the ovary tissues, and the teal dots are the genes that were upregulated in the testis tissues. The brighter the color is, the more differentially expressed the gene
is. The size of the dots corresponds to the adjusted p-value of the differential expression analysis.
Larger dots correspond to more confidence in the value plotted.
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Figure 3-5 Volcano plot of cancerous ovary tissue vs normal ovary
tissue
This figure depicts the -log10 adjusted p-value score plotted against the log2 fold change in
expression pattern between the cancerous ovary tissue (purple) and the normal ovary tissue
(orange). The grey dots show the genes that were not statistically differentially expressed by a
factor of 2 on the log2 fold change scale.
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Figure 3-6 MA plot of cancerous ovary tissue vs normal ovary tissue
This figure shows the gene expressions’ log2 fold change plotted against the base mean
counts of the data sets for the cancerous ovary against normal ovary tissues. The orange dots
represent the genes that were up--regulated in the normal ovary tissues, and the purple dots are
the genes that were up-regulated in the cancerous ovary tissues. The brighter the color is, the
more differentially expressed the gene is. The size of the dots corresponds to the adjusted pvalue of the differential expression analysis. Larger dots correspond to more confidence in the
value plotted.

17

Figure 3-7 Venn Diagram of cancer testis genes
This figure depicts the number of genes found to be up-regulated in the following
comparisons: 1) the left (orange) region shows the number of genes up-regulated exclusively in
testis compared to normal ovary 2) the right (magenta) region shows the number of genes upregulated exclusively in cancerous ovary tissue compared to normal tissue 3) the middle region
(purple) shows the number of genes up-regulated in both comparisons and are referred to as
cancer testis genes.
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3.2 Cell line gene analysis pipeline
To identify what ovarian CT genes are activated in ovarian cancer cell lines, we
evaluated differential gene expression in OVCAR3 and SKOV3 ovarian cancer cell
lines compared to BJ/HFF normal cell lines. We performed principle component
analysis (PCA) of the BJ/HFF, OVCAR3, and SKOV3 cell line transcriptome data
(Figure 3-7). We observed very little variation between samples of the same cell line.
We next evaluated our identified ovarian CT genes with a qualitative heatmap
(Figure 3-8). There are distinct gene expression levels between cell lines and very
little variation between samples of the same cell line, confirming with the Figure 3-7.
With this knowledge, the analysis was continued.
The next step in the cell line analysis was the comparison of the SKOV3 and
BJ/HFF cell lines. The results had the genes’ -log10 p-adjusted value plotted against
log2 fold change (Figure 3-9). There were 2,415 genes found to be up-regulated by a
log2 fold change > 2 in the SKOV3 line, depicted by the teal dots. The quality was
assessed with the MA plot to determine if the genes were differentially expressed
enough to continue with the analysis (Figure 3-10). The distribution of the dots along
the y-axis confirmed the confidence in the results. The 2,415 genes were forwarded
to the next part of the analysis.
The second cell line comparison was between the OVCAR3 and BJ/HFF lines.
The results were plotted with their -log10 p-adjusted against the log2 fold change
(Figure 3-11). There were 2,414 genes that were up-regulated by a log2 fold change
> 2 in the OVCAR3 line, depicted by the purple dots. An MA plot was created to
verify the quality of the expressions (Figure 3-12). The points plotted traveling up
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the y-axis indicated a high confidence in the gene expression levels. The 2,414 genes
were selected and advanced to the next step in the analysis.
The final cell line comparison was between the OVCAR3 and SKOV3 lines. This
comparison is testing a theory that there are genes in the OVCAR3 cell line that are
more highly expressed in OVCAR3 than SKOV3. We base this in that OVCAR3 is a
“worse” cancer in that it is more aggressive [59]. The results were similarly plotted
with their -log10 p-adjusted values against their log2 fold change (Figure 3-13). There
were 1,604 genes with a log2 fold change > 2 in the OVCAR3 cell line, depicted by
the purple dots. The confidence in the expression patterns were confirmed by the MA
plot (Figure 3-14). The 1,604 genes were advanced to the next step of the analysis.
The final step in the cell line analysis required determining if there were any
genes with the expression pattern of being up-regulated in SKOV3 vs BJ/HFF, upregulated in OVCAR3 vs BJ/HFF, and up-regulated in OVCAR3 vs SKOV3. The
intersection of the three gene sets found in this analysis was conducted (Figure 315). There were 87 genes that were found to have the desired expression pattern
(Table 3-1). These genes were passed along to the final step of our analysis.

20

Figure 3-8 PCA plot of the BJ/HFF, OVCAR3, and SKOV3 cell lines
Pictured above are the 9 samples of the BJ/HFF, SKOV3, and OVCAR3 plotted against
each other to show similarity and difference between the three different tissues, with the three
BJ/HFF samples in orange, the three SKOV3 samples in blue, and the three OVCAR3 samples in
green.
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Figure 3-9 Heatmap of CT genes
This figure depicts the relative expression of the genes identified as cancer testis genes
relative to the tissues of normal ovary, normal testis, and cancerous ovary. The first three
samples on the left correspond to the BJ/HFF cell line, the middle three samples correspond to
the OVCAR3 cell line, and the right three samples represent the SKOV3 cell line. A red color
indicates a gene with a high expression level where blue represents a gene with a low expression
level.
22

Figure 3-10. Volcano plot of differential expression of BJ/HFF line vs
SKOV3 line
This figure depicts the -log10 adjusted p-value score plotted against the log2 fold change in
expression pattern between the BJ/HFF cell line(orange) and the SKOV3 cell line(teal). The grey
dots show the genes that were not statistically differentially expressed by a factor of 2 on the log 2
fold change scale.
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Figure 3-11. MA plot of the differential expression of the BJ/HFF and
SKOV3 cell lines
This figure shows the gene expressions’ log2 fold change plotted against the base mean
counts of the data sets for the BJ/HFF against SKOV3 lines. The orange dots represent the
genes that were up--regulated in the BJ/HFF lines, and the teal dots are the genes that were upregulated in the SKOV3 line. The brighter the color is, the more differentially expressed the gene
is. The size of the dots corresponds to the adjusted p-value of the differential expression analysis.
Larger dots correspond to more confidence in the value plotted.
24

Figure 3-12. Volcano plot of the differential expression of the BJ/HFF
line vs OVCAR3 line
This figure depicts the -log10 adjusted p-value score plotted against the log2 fold change in
expression pattern between the BJ/HFF cell line(orange) and the OVCAR3 cell line(purple). The
grey dots show the genes that were not statistically differentially expressed by a factor of 2 on the
log2 fold change scale.
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Figure 3-13. MA plot of the differential analysis of the BJ/HFF line vs
the OVCAR3 line
This figure shows the gene expressions’ log2 fold change plotted against the base mean
counts of the data sets for the BJ/HFF against OVAR3 lines. The orange dots represent the
genes that were up-regulated in the BJ/HFF line, and the purple dots are the genes that were upregulated in the OVCAR3 line. The brighter the color is, the more differentially expressed the
gene is. The size of the dots corresponds to the adjusted p-value of the differential expression
analysis. Larger dots correspond to more confidence in the value plotted.
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Figure 3-14 Volcano plot of the differential expression of the OVCAR3
line vs SKOV3 line
This figure depicts the -log10 adjusted p-value score plotted against the log2 fold change in
expression pattern between the SKOV3 cell line(purple) and the OVCAR3 cell line(teal). The grey
dots show the genes that were not statistically differentially expressed by a factor of 2 on the log 2
fold change scale.
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Figure 3-15 MA plot of the differential expression of the OVCAR3 and
SKOV3 lines
This figure shows the gene expressions’ log2 fold change plotted against the base mean
counts of the data sets for the SKOV3 against OVAR3 lines. The teal dots represent the genes
that were up-regulated in the SKOV3 line and the purple dots are the genes that were upregulated in the OVCAR3 line. The brighter the color is, the more differentially expressed the
gene is. The size of the dots corresponds to the adjusted p-value of the differential expression
analysis. Larger dots correspond to more confidence in the value plotted.
28

Figure 3-16 Venn diagram of the genes shared between the cell lines
This figure depicts the number of genes up-regulated in the three comparisons. The bottom
left circle shows the number of genes up-regulated in OVCAR3 compared to BJ/HFF lines. The
bottom right circle is the number of genes up-regulated in the OVCAR3 compared to SKOV3
lines. The top circle is the number of genes up-regulated in the SKOV3 compared to BJ/HFF
lines. The middle intersection is the number of genes matching the target expression profile.
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Table 3-1 Genes identified in the cell lines analysis
ENSG00000005187
ENSG00000076826
ENSG00000100473
ENSG00000104267
ENSG00000105357
ENSG00000111344
ENSG00000124920
ENSG00000134709
ENSG00000136944
ENSG00000141524
ENSG00000149328
ENSG00000153208
ENSG00000160867
ENSG00000165238
ENSG00000168505
ENSG00000169896
ENSG00000172137
ENSG00000178826
ENSG00000181418
ENSG00000188322
ENSG00000197444
ENSG00000203867
ENSG00000224420
ENSG00000225756
ENSG00000232133
ENSG00000239830
ENSG00000244306
ENSG00000262160
ENSG00000271361

ENSG00000047597
ENSG00000077274
ENSG00000100505
ENSG00000104413
ENSG00000105383
ENSG00000113763
ENSG00000126878
ENSG00000136237
ENSG00000136982
ENSG00000143851
ENSG00000151025
ENSG00000154080
ENSG00000164626
ENSG00000165810
ENSG00000168675
ENSG00000171126
ENSG00000173432
ENSG00000179674
ENSG00000184613
ENSG00000188488
ENSG00000197587
ENSG00000204282
ENSG00000225210
ENSG00000228742
ENSG00000236081
ENSG00000240086
ENSG00000246898
ENSG00000266401
ENSG00000277268
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ENSG00000058866
ENSG00000092929
ENSG00000101276
ENSG00000104833
ENSG00000106852
ENSG00000117148
ENSG00000131187
ENSG00000136574
ENSG00000140470
ENSG00000147684
ENSG00000153012
ENSG00000160191
ENSG00000164867
ENSG00000167644
ENSG00000169242
ENSG00000171766
ENSG00000173557
ENSG00000180066
ENSG00000186481
ENSG00000189068
ENSG00000198435
ENSG00000214049
ENSG00000225383
ENSG00000229372
ENSG00000238178
ENSG00000243069
ENSG00000258733
ENSG00000270540
ENSG00000283172

3.3 Comparison of CT genes with cell line pattern
genes
The 5,478 genes from the CT analysis were intersected with the 87 genes from
the cell line analysis (Figure 3-16). There were 28 genes that were found to be
present in both data sets (Table 3-2). These genes will be the target of a future
analysis evaluating the mechanism of their misexpression, being both CT genes and
matching the cell line expression pattern of being up-regulated in OVCAR3 and
SKOV3.
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Figure 3-17 Venn diagram of CT genes and cell line pattern genes
The venn diagram depicts the number of genes shared between the CT gene analysis and
the cell line analysis. The left circle shows the number of genes expressed explicitly in the CT
analysis. The right circle indicates the number of genes exclusively expressed in the cell line
analysis. The middle intersection indicates the number of genes that were shared between the
CT and cell line analysis.
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Table 3-2 Common genes between cell line and ovary CT gene
analyses
ENSG0000010483
ENSG00000076826 ENSG00000101276 ENSG00000104267 3
ENSG0000011714
ENSG00000105357 ENSG00000111344 ENSG00000113763 8
ENSG0000014385
ENSG00000131187 ENSG00000134709 ENSG00000136944 1
ENSG0000016850
ENSG00000151025 ENSG00000154080 ENSG00000165238 5
ENSG0000018832
ENSG00000173557 ENSG00000178826 ENSG00000180066 2
ENSG0000021404
ENSG00000189068 ENSG00000197587 ENSG00000198435 9
ENSG0000024430
ENSG00000228742 ENSG00000238178 ENSG00000240086 6
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4 Discussion
The existence of a gene list at the end of the analyses confirms that this
method of detecting CT genes is viable. This is reinforced by six of the 28 genes
having been confirmed to be involved in cancer development and progression:
ENSG00000111344 (RASAL1), ENSG00000136944 (LMX1B), ENSG00000165238
(WNK2), ENSG00000168505 (GBX2), ENSG00000188322 (SBK1), and
ENSG00000197587 (DMBX1) [74 – 79]. It is intriguing to note that RASAL1, a
tumor suppressor gene, is highly expressed in cancerous cells, which would seem
counterintuitive to a tumor cell. Genes that promote proliferation are expected to
be found in cancerous cells.
Continuation of this research could have more samples of each of the cell
lines incorporated, and more data for the ovary and testis from TCGA and GTEx.
Utilizing more samples would increase the confidence in the genes discovered and
provide potential targets to explore the process by which they are activated in
ovarian cancer. It could be beneficial to run this analysis targeting specific ovarian
cancer types to determine if there are different genes expressed in different
ovarian cancers to determine how each ovarian cancer develops.
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5 Conclusion
Cancer testis genes are useful in the development of cancer therapy vaccines.
Understanding how cancer testis genes are activated in tumorigenesis is imperative
to determine how cancer develops. There were 4,578 genes that were detected as
ovarian CT genes. Comparing normal cell lines like the BJ/HFF lines to cancerous
SKOV3 and OVACAR3, there were 87 genes being matching the expression profile of
being highly expressed in SKOV3 compared to BJ/HFF, OVCAR3 compared to BJ/HFF,
and OVCAR3 compared to SKOV3. There were 28 genes found to match the
expression pattern of a CT gene and of the expression pattern set forth for our cell
line data. Our analysis sheds new light of ovarian cancer testis genes that become
active and creates new targets to pursue the understanding of the mechanisms of
ovarian cancer development. Once these mechanisms are understood, another step
will be taken in the treatment of ovarian cancer.
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A

GTEx and TCGA data files

A.1

Ovarian GTEx samples
Table A.1 Sample IDs for ovary GTEx data
11DXX-1426-SM-5GIDU
11GSP-0226-SM-5A5KV
11VI4-1026-SM-5EQM1
11ZTT-1826-SM-5CVLN
12WSD-2726-SM-59HLR
12ZZX-2026-SM-5LZV9
131YS-2226-SM-5P9G8
139D8-2426-SM-5KM3A
13N11-0526-SM-5IJFI
13OVJ-2426-SM-5KM3I
13QBU-1526-SM-5LU3W
13VXT-1526-SM-5LU3J
145LS-2326-SM-5TDCY
146FH-2526-SM-5Q5BP
14BMU-1726-SM-5TDE8
14PJM-2426-SM-686ZC
14PN3-1526-SM-6ETZM
15EOM-1526-SM-68723
15SDE-0926-SM-6LPIA
16NGA-0426-SM-7LG6K
18A7A-2626-SM-7LG6L
1A8FM-2226-SM-7PC1C
1B933-2126-SM-7MGXR
1EWIQ-2226-SM-7MGXJ
1F5PL-1626-SM-7MXTY
1F88F-2126-SM-9KNUK
1GN1W-1426-SM-9JGHP
1H2FU-2326-SM-9WG7R
1HSGN-2426-SM-C1YRI
1IDJE-1126-SM-A96SO
1JN1M-2126-SM-D4P2X
1LGOU-1026-SM-DHXL4
1LNCM-0926-SM-DHXK5

11EM3-1726-SM-5N9D1
11I78-1926-SM-59878
11XUK-1626-SM-5GU5O
11ZVC-1426-SM-5EGGA
12WSJ-1226-SM-5LU91
1313W-2726-SM-5P9IX
132AR-1426-SM-5IFF1
13D11-1126-SM-5KLYS
13O3O-2726-SM-5KM35
13PL7-2326-SM-5L3FY
13QIC-1526-SM-5IJFL
13W3W-1526-SM-5LU5I
145ME-1226-SM-5SIB6
14AS3-1326-SM-5RQJE
14DAQ-2226-SM-5YYAD
14PKU-1226-SM-686ZM
15DDE-2326-SM-6AJA8
15ER7-2326-SM-7KUN3
15UF6-2026-SM-6LPI3
17JCI-2326-SM-7IGPC
18D9A-0826-SM-718C1
1AMEY-0926-SM-72D6G
1C475-0426-SM-7P8OU
1F48J-2326-SM-7MKG3
1F6RS-2726-SM-7MKHA
1GF9X-2426-SM-7SB7W
1GZHY-2426-SM-9JGGK
1HBPH-2726-SM-A96TW
1I4MK-1526-SM-CE6T1
1J1OQ-1626-SM-CE6TB
1JN76-1426-SM-AHZ4F
1LGRB-2326-SM-CNNPU
1LVAM-1826-SM-DHXKR
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11EMC-1726-SM-5H11P
11P81-1526-SM-5P9GS
11ZTS-1926-SM-5CVLA
1269C-1826-SM-5N9E1
12WSK-1926-SM-5LZVK
131XG-1926-SM-5LZVG
1399S-2126-SM-5J2MH
13FTX-0926-SM-5IFF7
13OVI-0726-SM-5L3DD
13PVR-1226-SM-5RQJ2
13SLX-2426-SM-664OM
13X6H-1026-SM-5SIBE
145MI-2626-SM-5QGQ8
14BIN-1426-SM-664NI
14JG6-0626-SM-68716
14PKV-1226-SM-6871T
15DYW-2626-SM-6LPK7
15FZZ-0826-SM-6LLJO
16MT8-2226-SM-6LPK2
183WM-1926-SM-72D5F
1A32A-2726-SM-73KVU
1AMFI-1426-SM-731EL
1CAMS-2126-SM-7MXTF
1F52S-2226-SM-7MXVE
1F88E-2026-SM-7MXVP
1GN1U-2326-SM-9MQK4
1H1CY-1926-SM-9WG7X
1HCUA-1326-SM-9WPP6
1ICG6-1526-SM-C1YQT
1J8JJ-0826-SM-AHZ3F
1K9T9-2426-SM-DHXKT
1LKK1-1626-SM-EVR4Y
1LVAN-2726-SM-CNPQG

1MA7W-1426-SM-EV7A1
1PBJI-2026-SM-DPRYF
1QP28-1326-SM-DPRXZ
1R9PN-0626-SM-E6CR9
OHPK-2426-SM-3MJGH
P4QT-2426-SM-3NMCL
POMQ-1426-SM-3P61D
PX3G-2426-SM-48TZZ
QVJO-3126-SM-COH22
RU1J-0826-SM-46MUU
S32W-1226-SM-4AD67
S7SF-1326-SM-4AD4P
T5JW-0426-SM-4DM7M
TMMY-1726-SM-4DXTD
UJHI-1226-SM-4IHLR
WI4N-2526-SM-4OOSE
WYBS-2426-SM-4ONDI
X4EO-2426-SM-4QASD
XUW1-0126-SM-4BOOQ
XYKS-1726-SM-4E3IO
YFC4-2726-SM-5IFJW
ZC5H-2026-SM-5CVN2
ZVT2-0326-SM-5E44G
ZYY3-2726-SM-5EGH4

1MCC2-1026-SM-EVR5I
1PIEJ-1626-SM-E6CP9
1QP67-1526-SM-E76P4
1RDX4-0826-SM-E9TK7
OHPL-2426-SM-48TDN
P78B-1926-SM-3P616
PWCY-1326-SM-48TCU
QCQG-1426-SM-48U22
R55G-1526-SM-48FER
RU72-2226-SM-46MUE
S341-0726-SM-4AD5R
SN8G-2426-SM-EVR31
T6MO-1126-SM-4DM5D
TSE9-2226-SM-4DXUR
W5WG-0926-SM-4RTX9
WWYW-2726-SM-4MVOP
WYVS-1526-SM-4OND4
X8HC-2726-SM-46MUA
XUZC-1026-SM-4BOPY
Y114-1726-SM-4TT7U
YJ8O-1026-SM-5CVM5
ZLWG-0926-SM-4WWC3
ZVT3-2626-SM-5GU5L
ZZPU-2126-SM-5EGIU

44

1OJC4-2026-SM-E6CQW
1QEPI-2726-SM-DPRZ6
1QPFJ-1726-SM-EXOJU
1S5ZU-2326-SM-EAZ5B
P4PP-2426-SM-3P61L
PLZ4-2826-SM-3P617
PWN1-2426-SM-48TDD
QDT8-2226-SM-EZ6LT
RTLS-2326-SM-46MUH
RWS6-1026-SM-47JXD
S4P3-0926-SM-4AD54
T2IS-2026-SM-4DM6W
TML8-0926-SM-4DXSJ
U3ZN-1026-SM-4DXTC
WEY5-0626-SM-4LMIA
WXYG-1426-SM-4ONCK
X15G-1726-SM-4PQZN
XMD3-2326-SM-4AT5H
XV7Q-1426-SM-4BRWA
Y3IK-2026-SM-4YCDG
ZAJG-2726-SM-5S2MU
ZV6S-1426-SM-59HKX
ZYFG-1726-SM-5GZZB

A.2

Ovarian TCGA samples
Table A.2 Sample IDs for ovary TCGA data
0045a228-1dad-4ced-9bc6-5067aeee0518
01a7573b-1ced-444d-9cb8-44212a30f878
0315439e-694c-4b14-a27c-29dfa117c764
04098317-63b1-43eb-9b7f-e8e619e52781
0495ff8c-8878-47b4-b10e-660d7252e5de
053f5fb2-8b5f-4252-82fd-ba167a58c23f
06199259-c8da-4b44-b957-8148e31b38cf
065393c7-9928-4fdc-9dbf-68ba9c708561
06affed3-2a28-4fe6-8c16-b9432050bff6
08dd298e-9a5b-495f-8f5f-42998ae6dabf
0991973f-cd4d-4fcc-bf95-ee735422abb6
09f70243-303e-4312-9913-ecc76f2cee3e
0ab0f22f-bfeb-4a5e-bd8f-f0fb30eac992
0e52e958-9450-4c3e-b169-5ed4a63f044d
0fc26774-1494-4578-97df-7b4fee07483b
111d4d64-e1cc-404d-8fa9-ca0a545041cb
12c8b289-b9d0-4697-b3a6-db8eed617937
15241763-4cf7-452e-bc24-b3d877348b2d
16b391ee-1f65-4665-bf34-5447eed6800b
16e1bba3-6db0-429c-bfc8-82f27c8a3252
1865f7a2-31da-4e7a-8cd5-a4c15372ffaf
195a13be-31a4-47ce-bc3d-6aba8451e304
1ade6fa3-de71-4760-9760-8abc10963255
1c314a2a-c268-4c89-a6ee-c679aff9052e
1db081ff-e475-412c-9f55-fc5face40558
1e10d520-3bcf-4edd-93d0-03be32f7e8d7
1f2dbb8e-0713-4952-a9e0-70fefa263116
20c77d79-6934-40ce-b490-54221196a090
2179de4b-5872-4129-82dd-ef19dc540898
24a15ca8-0811-4131-baa1-94f904973ecd
24b7176d-483b-416e-8ecd-d3beae934fc3
25577d95-744c-45a8-b84a-a9c1b51c2baf
273c58d9-1f2a-491c-8487-408f751a7a3b
297978f4-9907-482f-89db-3a0a2a0f19a8
29d09b58-3cc2-47c0-b78e-18743eed2c2f

01770ca7-0c13-4078-b956-a35dc68fbe28
01eac123-1e21-440d-9495-8b7a4166249f
03c8a50d-0484-42e6-ade8-d214684f62c9
043993e1-370b-4bdc-8783-be65b97ed886
04adbacc-4d08-42ff-b261-5262344b08f3
054352e9-a6fb-4f61-b524-2741017c2bbf
062b6d0c-06b0-4d27-8702-32501278cd9c
06884e47-0650-4748-9f4e-b8cd9f24795c
076b33da-f743-41b3-816c-cce371a527f7
094dbc70-aa59-40b1-8ceb-1ce6e5e6bf01
09ca93e6-6ff3-4e50-ba6a-34e5eb7c39b1
0a398afb-4549-40f7-83e7-ba33739965ad
0d11c451-2dfa-40ed-93fc-261d94f299f3
0f878485-4f73-45ec-8d2d-b89850813aa5
0ffb5d54-6522-4074-9c41-8371f284d1dc
11f80ba0-162f-417b-96b8-4d21ddaef88d
1475a657-0f90-4308-a59f-f6c51f60216c
16417d82-1ae0-4097-85c1-5e2df313fd35
16ce29ef-a16f-49df-9ee1-630f229208f7
178c423a-3ae9-4343-aa81-02292024e421
1902f5f0-8474-4f4c-a17b-f813fe02ca58
1ac930e3-e67d-410d-9182-44d85799fd18
1be906cc-a22b-4c94-975b-d0d68257f4da
1d6a0834-0561-4d45-813d-1ea499b613c0
1e0f7f1f-e4aa-43e6-a6c1-bc4a0439d3af
1e918517-3a1f-45ae-953b-b65ecfaffd2d
1fbaa35c-4ff8-49e4-8aed-4a20b408f840
211b9b7e-5a5b-4da7-b75c-4a0a738cdaed
21fccc2c-bc60-4ed4-ba78-5dfbb0d5f498
24a828c5-596e-4a8a-ae44-9787841c6978
253d376e-81e8-446f-ace4-985184741bc3
25d6dd26-51c7-40dd-962a-c00abb70c5cb
276e88b0-deb7-452f-9499-bd770c72f0cc
298026a5-291e-4376-bb5b-e1f063843235
2a07ad59-da28-44da-8da9-d948186c99ff
45

2a4a2670-4ad4-49ac-8571-477c44201219
2ad2adf3-212d-42e5-87df-a4025e900584
2df4d9b2-5c9f-4952-bd5b-62f1a244f5f1
2f635d92-f453-41c4-b5e8-d7c3256877dd
30bc60d4-7bf1-474e-a2f9-3c1108820cd1
3146c2ae-ff5e-4097-8005-f4d261af032e
320a6126-c3fc-483f-b79d-b15700a51997
3344d45a-7ec5-4d77-8d77-b95aa55b7f4c
34e382cd-6fef-4386-8a30-cd1c8f889f30
36a15497-1f35-446d-886f-ea34196a5fdd
3769209b-a12f-4a84-9d68-0e1c934e5aea
38721491-84e5-4eee-92d4-fa8f8cf463f1
39cf924a-ed8c-4a0e-a7a6-beea001be23b
3ad93b22-6d06-4c58-b365-2a0558bfb5f7
3db0253d-7bc6-4d7c-8c8f-fbfefc3556a6
3e3fc76f-8ff8-4679-9bb4-37d0509a92f3
3f04b67c-ac10-459d-a661-dc1ee3963311
4013973f-bab5-4844-951c-c80f34fcb828
41060841-8b20-48b9-9bfc-fa669d36d635
42d8c04e-0355-455c-b982-581727f75665
43b0eb35-8278-440a-a743-fd91ca544b1b
45197059-d0fc-49bb-819b-bd7621427236
4524f1ca-c763-47af-8f80-331c64704d7d
45c99019-ad30-473d-af3b-2fa0ccb819b9
462e7d42-19b7-4e95-bf2d-d2a66852f6cd
47ecef21-f50f-4da1-a267-4466eca80b28
4a67d3fe-88a5-4255-89d2-7814321cf6ab
4b4d6cbb-92b0-4c40-8338-5acdf5f3f2a9
4c6f3410-7bb6-4be3-a4d1-b3717279b212
4d337bb6-8e53-4142-8c22-432bce3e754d
4e4b6800-a128-4daf-a9f9-803b24e04742
4e63ba56-ce7b-4f2a-9b87-aee011ad13e8
4fc22ec0-632d-4491-9d3e-99878010a689
511ebfdb-5384-4dac-9ea3-8916b541a7e9
51b8dd7e-1686-46bb-9a29-b0a368eaadcc
528fc2fd-fded-426d-a62c-af4ba50e9645
5327762f-5add-4008-ac5f-beca30ee5b4d
53ff71a4-9487-4ae6-9d25-f55cfb70cf81
568de3f5-ff1b-4dc2-9a8b-1a3034e58ee0
5817ee66-fd3b-413a-a479-9a89a5a28a99

2ab2d4f1-4171-4326-91e1-e2c795004468
2ad549b2-56d8-4047-a398-cbe1f6295722
2e01d725-ae04-49e8-9a45-52634cde5662
30b1f3cd-604d-4a13-a196-1216658c87fa
30cff944-ebc0-425e-8cd2-e509ff218471
31e45387-5c86-4d8e-9b54-da954ee4634f
32c77c11-20f5-4719-b668-b2da53c914c2
347a8eeb-204f-41df-98d3-61394d2b7cd7
353ff7d9-113b-4802-8cc4-635cd44b8706
374fe6df-3752-47d9-8060-f9e5d05750e5
3788684a-b405-44fe-8d09-4e40a46d5214
39ae7d32-a9c6-4599-a860-5c25e05899fb
3a34e792-461f-45f5-9c4e-a29deeef9ce2
3c052e47-a4d4-4e13-a67b-b50fd1b7cbe5
3e00e8aa-31bc-454e-b558-7bcbad5f47ad
3ef6bcf6-93a8-4c7c-b2c1-9c48fba76b32
3fe6e5df-486e-4887-b79a-89a1591f4a29
40b41560-b08b-47a7-8149-b73c9d00d25c
41c1021b-1086-470b-9907-afe11444ed3f
43622957-7bed-4d24-a31e-5fadf41216e1
44c2a2eb-6671-4951-9088-cdf4c23d60d8
451aa144-4d34-4858-b81e-3458db34892b
45b64a61-30d8-4ecc-909a-803be9c3ff2f
4610ddcb-2924-4d3f-9d2a-b6416f7c3f03
4722ba18-27f6-480d-975b-59742f9f0f89
48297930-d22a-463d-80ac-52214964f067
4b449f26-ee8f-47d1-9d93-de9ceb61ffba
4b63696f-c8f8-4601-8751-d8efda9224a3
4c8d97ab-39ad-41b9-b7f9-3aa56f373c2a
4e1c9b43-bfd3-4242-9d55-66ad4b66d84f
4e618fff-4f1a-403f-bfb7-3a613758383c
4f715b36-328a-4d62-8cf8-28cf65f73841
5112a69c-c9ec-4c72-b93d-31f110d74eb1
517d7f3f-2ea0-4452-a743-8d0e3083a1bb
52292cad-9758-4d1a-8162-1f883ff327c0
52a3d27b-f415-4e7c-8000-957574724cfd
538a1fe4-8e69-4a29-a789-da52c075e75f
56427511-2167-465f-bdde-689b895b3d4b
5784a937-f090-4866-8d8f-e7cbbb3e327d
58d3df78-134d-43aa-a7cb-0e07db7e325e
46

58f06031-8e8c-4865-8cea-ba65d28317a9
59633988-fe8b-4f38-a6ef-06910fef0846
5a8d910c-004f-4368-ad4d-0e8deec45384
5b23f813-9970-485b-8577-ab2f3c029c26
5d0bb715-68ef-4688-9d58-0f18478e6a5c
5ee01776-d2f8-433e-8dca-761151099491
608f7a0f-75a7-425d-9a82-6bf7e2023138
60da3a1a-65ee-48fa-a08f-88b6d52a18c2
60fdab7c-849a-440f-815a-c67741e1106c
623e04e4-491d-4381-8c11-b64ece9a4c31
654acb8d-c1bb-42b1-91af-4f0b37abf02c
659a82b6-9aae-4aed-8df7-964697ad1640
65ce7190-f1ef-496a-8e47-bcedd8dce223
660a745a-f0a2-4439-b3f3-51a60132b97d
678a3fad-2c4a-450f-ae1e-8258fc8a618a
68339551-7f92-4000-b0ca-d33669bb2c39
68ebef00-5c43-475a-9117-33ea920cab69
6aa7225b-3d10-4b19-a472-0adeb21c26cf
6c962389-a73a-4627-8a2c-41e4a1cc8df3
6e6ab126-1ab3-428c-b780-a1a98c475154
7024891a-6a74-45d1-813d-7199707c45c5
715d1493-6c47-4f20-bd62-c08d4f3870de
72251745-4686-4ce0-b70e-5a0444b36b59
72bb9902-d411-494f-98ca-0e273967b96a
7394d96b-2719-4eb4-b776-439171584f2a
73ed989a-7f6a-4cff-a7f7-f99157535c7b
75303476-cdec-4ae4-aaf5-01abdc3213ab
7570289f-debf-40f9-9e2e-c5acf19626f4
75fdcd7e-f701-4c93-b3cc-22ff09b770ad
765c9c00-fbd8-4dac-89da-a4cee971e8bd
773a7fb2-61e4-4a6a-9eab-1cddcb8b83cd
7849325e-0e51-4696-bd8e-14e0b0cf40e8
790570e9-099f-4458-88c9-1ebe12205a67
7a7e4b6b-de2d-4e49-bcbf-c705164477b9
7b632a5d-f69e-4fc4-a33c-73c3ff85a42f
7b707153-0a5f-4923-a3d3-a53a798d4259
7d1a066f-8791-45ff-98e5-f4eb3d1e1d8d
7d9443ff-9ff5-415e-b327-bc71d6cbc4b3
7ee8ec85-e646-40c4-beef-5b8e8ab35168
7f3810b3-4ff8-4a86-944e-7c87cf5593a2

590b183e-6bd5-4e23-b41c-7301575c4aa6
59bebce4-6006-42a6-8d73-c6ef8fb3c9ce
5a928267-356d-47e9-b8b2-f477eaa261fa
5cf0bf40-6b9a-4bcb-a88f-7256a298c5ef
5dbeb062-22ba-4057-afd6-8627f1ac9500
5fa4dd02-be02-480e-a8ad-ae89bddc17b9
60d09a9b-add7-498a-a4a3-3e926a23dc1d
60deafcb-603b-4eb8-92b1-28656a674581
61b6a3de-8bb2-4fc1-85d9-849c823d8fd5
64430665-49d5-49d4-9ef8-7559cbfcabf8
655c5a8b-a87a-482e-95cf-1519b3146534
65c32518-eda4-4a4b-8d39-00a28936664d
65d87c44-cb1f-4889-bdfa-4788f7183ae1
662e7355-e7b4-4d12-8429-f53b7b70bbe6
67bee95c-2a85-443b-b662-28103dfefdd4
68975d5d-407b-4ceb-96d3-8e2a37ca3c1e
69134f9d-2738-4fc7-820d-0fb80b699480
6b9a94e7-144b-4a17-97ed-75f7cd311baa
6e40a1e7-9ff6-455f-8f70-77611a66088e
701b8c71-6c05-4e5b-ac10-396d245d62ea
7093a0f5-822d-4f61-9adb-fe9adbbff769
7163f82e-33ef-4a92-946d-7dd07a9657af
726b125e-47ab-43da-9737-f8cba68fbeae
72dad4d7-0138-4de3-924c-119658aa9084
73bc4ef3-2d63-4829-a28e-f400abf4290a
74318679-8eae-42ee-8721-fd38de88938a
756efdf3-3d00-42dd-b854-0054444a7de5
75d8a8c7-bc64-48f4-8fe9-a0e7640e0b44
760e59a8-b3bb-4d63-9e0e-23b5023546a4
7707599c-51ca-4801-adf9-1c9642254fdb
78362a69-6a41-4c14-8e08-4fd7773ce03a
78c27c9c-843b-4e6a-a36a-1aa4dcb8decf
7a181264-18d3-4a81-b8c1-43e08ddab953
7ac80350-d086-4aff-bbb9-a38a57d4cf28
7b6e2a12-c537-4f1f-911f-d430bd864d2d
7c4769c1-1907-47ea-98f7-26cd438d022e
7d5d98d6-91b7-470f-879c-8e83ab4d3fc6
7dfc4c0f-bb68-4ac1-95fc-e2a3fee16704
7f0f3d94-1376-470a-a959-cd56039ae10a
7fb4f0f7-027f-4cf8-b8bc-43ca398c46e8
47

8166ba38-a099-4a07-8271-0587fe8d10d7
825ebcdf-3e59-4d89-9f6d-b27c7dc896d1
84156df8-23f4-41e0-b305-e4812fded4da
85c382ef-b9c1-4c1a-8ef1-5a2fbbb5f72a
85fe5749-1fef-49a2-bbac-9200c3c5a1cb
86cb28d4-5dcd-4e7e-a4c9-c5a5b16a9739
875c2a27-9732-4b8a-affc-8ea591595a43
87fd11ca-f797-4336-8e23-c8c0ccef6b0c
882d61db-f3ae-4c4c-8d2d-32c18b597624
89758e34-511b-465a-81db-2af07f047d5f
8beaeffb-5e9b-4589-8999-52c3d736aea7
8cfe4a4f-7ca0-49fa-8820-99321c22176d
8eb0f5ac-1196-4cc5-b25b-f9e76301772e
8fc333b1-b2ee-4eff-afa9-8606b282a341
90e896dd-f619-4a9f-b386-d060c02bb876
94823ae2-8fb8-4be7-b2ca-88dff791b29b
95ce6307-6006-4b0e-9fa7-942551eaf05a
97d62176-1e34-4508-886b-df643f8a7e75
995b85f1-d46f-4989-a4a0-2a73b5df69bf
9a420e2d-15c8-41f3-859f-25872765f75e
9bca614a-922a-4bef-8a96-c2b71dcaf17f
9c6f2d76-7701-434e-a876-c04ab14cccea
9d80d1a6-3a9c-42ca-8139-c88659088638
9e198dfe-9fc6-48e2-ba06-90c49ddf48aa
9e623149-b279-41fd-9be0-5d20d8cc024b
9f8c8f79-2581-48fb-90bb-5d3e898689d6
a085cea5-b7ca-449c-b218-07c7715ca736
a1c4f19e-079e-47e7-8939-3122c56bbb98
a2082ad4-279e-422f-b5a7-cb7fbeb7a6df
a46fc22b-4074-4184-b471-c372139f9486
a5929721-d8ba-4b73-aa2f-c4903fb380bb
a6542a39-6092-4a62-aa6d-51bfba48ef10
a6bbe2d8-2f21-4eaa-b2ed-4da1ff48054a
a72d4647-2034-4bc0-9a58-db0f97b7e76a
aa77a3af-80ce-44d2-b227-faec0f734468
ab8603dd-2f94-4c83-9927-455958be0007
ab9f8d1d-d981-4139-8191-ad8db91c187f
ac6e38b7-143c-491e-9892-4c28f51ddce5
ad9a29de-7c46-4caa-a802-b18053b4e32d
ae0eb407-7bf5-4023-a297-470c93e15d3d

81830d92-01c0-4607-888e-be947ccae6e2
829fbe64-5c02-4a8f-96e6-9e251c776107
84e6af70-0c66-410c-9fad-6188151ef356
85ca6ac2-6cec-4249-9166-54a2f0e10404
864f36c5-41fa-4f90-b737-e164ce1eb845
871da002-8649-42bc-8ce4-9d2a8ff66213
87ccd166-7fbd-498c-b03f-d4c369ff30ef
8822cd66-d592-4601-a81a-caf939cb8882
88f9c446-a966-4131-b379-63e3cc1b7aa9
8bb54b5a-d23c-46a2-839e-32355236477b
8ca881ca-da4d-43f3-9d6d-1ec5289927b8
8e0d147d-16de-4d8e-b9f6-5e493917b7b5
8ed16638-71b1-47bf-9fbf-1e9efee46e07
904f8983-9011-4b3c-a5f6-94fca0a0573a
92a8c68d-23ec-467f-84c0-4876b71359f8
95595a36-1582-4fb6-bf79-f0111b0abfc9
968544ba-7990-41e8-a0ee-5206ceeb47ca
98e7898a-bd2e-4c49-9f76-aea65d7960a3
9a111391-cea9-47b0-bb5e-2bd19ff09a5a
9ac17699-409b-4750-9317-aacc8c04da46
9c330249-5ea7-4795-98c1-9c8f2cea6ac3
9d2d7bcb-8af4-4143-bd1c-b7b5a239795f
9d904376-a13a-4827-a3f5-3772f579e5dd
9e51cba1-f13e-46a1-b37a-99e6db2d6134
9f223240-1020-4450-a6ec-a6168a9211e5
9facd5d5-33cc-485f-b80a-b613f936f2d5
a090ec54-edf8-4188-9bfc-add752bdaefa
a1ca5d5d-d468-476a-99be-0d6ea90f6533
a26fe084-f208-423b-ab61-6d34598c9cad
a528840a-20b9-40ed-acfa-46b8b52ffef6
a5d9ce27-ad5c-4d0a-9494-b0d75c00f80b
a65ae799-abca-4512-a65f-04f775818ab2
a6c5d247-364e-41c4-8a89-dda2410dd3af
a7ce619c-20e3-4a20-adee-1b1d0c367e76
aac2baeb-b9e2-4e94-82c5-8d591d90cf91
ab89687d-2019-406c-95e8-a189c13c9fc0
ac6dbd3b-d3fc-4126-b637-e6be2e7454db
acaec383-b91d-46a9-a1d1-6eb4764cd000
ade137ec-8b83-48d0-9162-4a2f52db5b0f
aea568b9-f9d8-4458-89fd-894c9e9ecb57
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af11caa0-a20b-4c17-8207-0a1142edd9a9
b00351d7-1785-4157-9955-aadc2f195181
b14d1cf5-7063-4d0c-aa27-bf2802102751
b1d5c444-da0d-4360-bd45-31c94217adfc
b2552f6f-dd15-410f-a621-195d90f44831
b2838a0f-fdea-4d0e-b908-d09e866035f1
b2ccd224-e50e-4dac-898f-83bda68866e8
b3b1dbca-bce2-40a3-92a4-848f616b98e3
b4f37e7b-e458-4395-a204-8a1dad62a28b
b64ef80a-d41c-4f92-a3ed-e43d55abb2c2
b9aa8d09-5536-4b37-8259-8018bfa6d886
bb2408ba-58c3-4ee3-8ddc-1af4e1394b94
bd0abda0-f330-40f3-b06b-1f6c8f5c667a
bde7dae9-5985-4195-b22b-cc0babb99c75
bea1858a-5de7-48ee-9fc3-f9abdd4b0ded
bec22c57-3929-4fd0-8cf8-314cf4666719
c255d022-a659-42bd-9099-6853b41b64c7
c2de32e3-b9bc-49e1-9dbe-8c09b48ff637
c6287ac6-570d-4431-87b3-290db2dbe58b
c65d79cb-b639-4030-97d9-ddb84bc39195
c9689d9f-6138-42a8-a58e-1b44dc4b193f
c9e12ef8-5bf6-496d-8c8a-e0596c2f1d7c
cbe087ce-2924-4c5a-b307-51c80b41d6d8
ce511378-d8f8-494e-a07d-2e0dbed68bf8
ce9deae0-fdae-4c71-baee-d9054fdd0f77
cf3d8158-3e8d-47ba-8569-e976c8e8e1a6
cf926727-8d8a-4dea-87cb-18aeb4ab216d
d0744791-f4c0-45c7-b233-c6512f3c766b
d1245eee-b6b7-42aa-856c-79148869cb2b
d143ba0b-3878-428d-9432-2a179a9abf8c
d15fbebd-39c7-4714-b6f3-fe920cdd8bef
d2e8bf06-abd8-4703-a4a0-29cf6fe01d18
d4653d1b-2cfd-4d30-938d-7b12b66b8aaf
d5159274-e487-430f-8204-02653f41690c
d687d704-1868-4120-9445-186e15cf6216
d73c0f69-ab9b-4408-bf89-aa34bf829351
d7e6e15d-d26c-43f3-b0a9-d5a4dc861e9d
d94e4aa8-366d-4330-a08c-b543fc0bd18e
dabdc0ac-e436-4140-ba66-52a7d7c50ee0
de855db4-12d8-47bc-855b-96f61d306541

af6e5654-e755-4c15-b3e5-807da2642e25
b065b395-20b6-4417-b4c8-d8161b5a9db2
b1808878-10a4-4024-9359-70d7ef17a439
b244d2f7-122c-4529-8fcc-c19e2c719cf0
b269c35d-7f91-4c66-8bef-59906ec87745
b28d6dd2-923a-4160-8876-7b0fbb7a7a26
b322d383-64cb-4033-9b44-872ad37acc4a
b4760c72-6405-4b0c-b13b-dbef127b7ffb
b5381bca-ac72-41f2-840a-f7f23382fdd3
b90ceb09-1097-4c53-ae4d-0e7acd0ea8df
ba8ce34a-28bc-485c-af2e-1c835c351997
bb94288a-d4c4-4811-bcd5-7306891779fd
bd727430-2539-4897-a754-2c8d8de59f9e
be626971-cdea-495d-88cd-1323e7c23fe7
bea2f6be-177f-4454-8831-0d287cac265b
bf4058ee-ed0b-43e4-bc4e-3343239f187b
c29d7649-364a-4fe5-9dd2-9f8937a565e4
c5e8e5e5-91e0-4e3c-97ad-e1cb63aaf70a
c62a3590-7d1d-4a46-b021-279e7a36b77e
c773cdc3-7702-4833-9b12-ba954ac4b357
c96b872f-d842-4e6a-8845-59308a28c279
caa50267-cc68-4ccc-b506-49a89b163510
cc7bfa3f-7301-44d4-b29a-35905c59eae6
ce515bac-2166-4e01-a3f7-fa822fe8b7d5
cebba8db-616b-49a5-ac4c-c3bee701e48a
cf7f32fa-03aa-441e-92fb-e2fd5df5bbc0
d04892ff-0ddc-45d1-93a7-abe21c67eb94
d0e4aa5d-e918-4156-99ba-14b14a2a9975
d12e86a0-97a4-4260-9c8a-0122931addf3
d1488c77-de3d-4bfe-aee9-7c398f62d8ec
d26ea6e6-8770-486f-9d79-249e5b039606
d3d0227f-bf96-43be-aee0-d11518748e11
d490312c-c941-4336-8b94-163881b72be6
d522e111-8a5f-48de-b894-1bf7505bda98
d7191f19-150b-4175-83a7-21052fefc488
d7be2882-fa19-4a0f-937e-286066dd0642
d85fe825-5437-4717-8848-45e1290dd928
da436927-a3f5-4f12-b63d-d6f13f436ab7
db2f54d8-82cb-48b2-a3d4-1fb7daa8e75c
df06bca2-4481-455f-98b2-4c1981698f56
49

e04f45cb-e226-47b6-8e15-5bfcdec1a078
e28ba1c3-344d-45d3-904b-cace53ca78d0
e360132f-9b30-4d44-ba1c-68941706d9ee
e47d5da5-4752-46d0-846f-f626be1793ed
e5c1e1c2-d80c-47a1-9f18-8125b186b1cd
e6cbc9a5-b8a2-485f-abc5-e66767520680
e78e6e23-183e-4492-8b69-28cf7c2623f4
e8bd5099-de91-4c44-8573-f5eaba611dfe
e9841cd8-c4a9-49ac-9d53-6b808d82ca8a
eb329194-22d5-4675-a982-0c2dd8e5a324
ec380f9e-879a-44cb-b16c-2a47417a09d0
edbf38b1-342c-44a6-8d6f-b5bc871848d8
eeb18b62-a0f1-4af8-8115-cdaeaeef0f32
effcab37-0ee4-422d-9d51-5cdbb78d2db9
f0586e76-31db-472c-9ccb-4c63fdf5cd15
f12b9d7b-1b32-43e9-a496-0794db75f69e
f27920c4-1504-45ef-8933-65f42ec9ab98
f562a9d0-39fb-4062-b535-87a96ad3212a
f72d0be0-de49-402e-8c92-4968ae079973
f7722eae-ade1-4087-a6d7-aff561972b73
f8397fad-30b3-41a1-8d44-52d939e77a06
f89131d8-8ee1-4733-b97a-0447f7ce601b
f920e615-9b0a-4767-821b-201c407730c4
f9dc7237-e186-40e8-ab4c-d142dba7cf3d
fa3553e7-0255-4d60-b8c9-3caba0d945cd
fb4b490a-de40-4f75-919d-4fb180647eca
fd15971c-b78e-4bba-bf87-59cd758b7cc6
fda19653-d2d3-41f2-9122-72e892fd2853
fed23e32-490a-4849-b335-d6cc8f0187fa
ff2264ee-19ac-4f74-b3fe-eaca826ea493
ffa465fc-7af9-401f-af3c-bca394a1ab25

e0b32572-2ff9-4929-9917-83624e63aa2a
e2cf2389-07bc-49d0-9426-82a98728a685
e377a906-e48f-4f6c-998e-7f914b8cd712
e4a4badf-b4f9-4729-bec7-191867c7c229
e6993299-9429-4689-acb9-1fff67ce6642
e78cab9d-1b43-4416-8dbc-78d51558d895
e8b90f89-c047-404e-9e04-5589ff43495a
e956031b-931a-4ccc-b0d5-51cb1ab9baed
ea70df70-0135-4ac7-8f65-f2b7839ebc23
eb4572b5-43a0-4d92-ab9c-1c5853710297
ec69e15f-b3cf-4f42-94ed-72d80565a1b6
ee8019df-d2d2-4a32-9ef4-6da186fa2866
eeddee84-15ec-401f-95ee-de2bb7015168
f00793a7-8ba8-4486-95d1-3ea0beae2508
f10f8b8e-c6e7-46e1-a97d-08f90c76b539
f1b52b3a-9748-4862-ba4a-a8f8e8a0166c
f3c8c91a-71e0-4b1d-a03f-06ed0123ce9a
f6a67523-d202-4ce7-af2e-b2cc4d8db20a
f76c1066-d6e9-4d27-a0ac-0a493d8e85f4
f7d12919-2133-403d-9492-155e4666fb94
f84a525a-7fab-4c5c-b37a-6027787ee817
f8cef5ad-7841-4f50-ba42-55e11ed1fc36
f9bf79a2-9d3a-4df1-a03d-5a9dad5b5fbf
fa2df153-c852-4df1-8499-fe2517dee301
faf78582-3ccd-4ee7-8193-92ed0945fd6c
fb9c5a20-75cd-49f4-b75f-09a054e72267
fd638406-d933-47da-ba38-8ffc5046d49e
fea3c4d0-7b9f-4279-989e-535aaefbdfeb
fedd52be-18a8-423f-ba8a-4f9416f11ff5
ff54b7b3-1622-43f7-a9b3-96a99384999b

50

A.3

Testis GTEx samples
Table A.3 Sample IDs of testis GTEx data
111CU-1726-SM-5EGHM
111YS-2026-SM-5EGGL
117YX-2026-SM-5GIEF
11EI6-2226-SM-5EGJM
11GS4-2026-SM-5N9CP
11NUK-2626-SM-5A5MB
11OF3-1826-SM-5987N
11TT1-2226-SM-5GU6B
11WQK-2826-SM-5EQKH
12696-0226-SM-5EGL3
12WSH-0326-SM-5GCNH
12WSM-1326-SM-5GCP9
13112-0226-SM-5P9IV
1339X-1926-SM-5PNVP
1399T-1526-SM-5P9J6
139TT-2226-SM-5LZWO
13FTW-1326-SM-5LZZD
13NYB-2226-SM-5MR58
13O1R-0726-SM-5IJEI
13OVH-0726-SM-5N9BU
13OW5-2526-SM-5L3I1
13QJ3-0226-SM-5S2PU
144GM-0426-SM-5Q5C8
145MF-1726-SM-5LU9H
14753-0626-SM-5Q5CY
147JS-0126-SM-5S2TW
14ABY-0626-SM-5Q5C9
14C38-0126-SM-5YY9V
14DAR-1126-SM-793AT
14E7W-0726-SM-664OK
14PJ3-1626-SM-664O5
15G19-1326-SM-6LPIR
15RJ7-1826-SM-7KUMJ
16MTA-1126-SM-6LPJA
16Z82-2726-SM-7KULV

111FC-1926-SM-5GZYC
117XS-2026-SM-5GID1
11DXY-0226-SM-5H123
11EQ8-1426-SM-5EGJR
11LCK-2326-SM-5HL53
11NV4-1726-SM-5N9FC
11ONC-2226-SM-5HL6D
11TUW-2226-SM-5EQL9
11ZUS-2726-SM-5FQUA
12BJ1-1326-SM-5BC5P
12WSI-2126-SM-5GCMV
12ZZY-0126-SM-5LZV2
131XE-0426-SM-5IJF4
1399Q-2826-SM-5IJEZ
139T6-1226-SM-5IFFC
13FHP-2826-SM-5IJFW
13N1W-2626-SM-5IJEP
13NZA-2526-SM-5IJFX
13O21-1226-SM-5J2MK
13OVK-2226-SM-6LPJY
13OW6-0126-SM-5IJGM
13VXU-0726-SM-5J2O7
144GN-1626-SM-5Q5BU
145MH-2326-SM-5O9AW
147F4-0626-SM-5LUAK
14A5H-0626-SM-5TDCO
14B4R-1026-SM-5TDDS
14C39-0526-SM-664OF
14E1K-1926-SM-73KWS
14PHX-1426-SM-69LPP
14PJ4-1726-SM-664OC
15RIE-0626-SM-6M47G
15SKB-0326-SM-6M477
16XZZ-0626-SM-6M47T
17EVP-2426-SM-7IGNK
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111VG-1926-SM-5GIDO
117YW-1526-SM-5EGGP
11DXZ-2126-SM-59881
11EQ9-1926-SM-5PNVV
11NSD-1026-SM-5N9BE
11O72-0726-SM-5P9GO
11P82-1526-SM-5BC5M
11WQC-2326-SM-5EQKE
1212Z-0326-SM-5FQSJ
12C56-1426-SM-5FQSW
12WSL-2326-SM-5DUXQ
13111-1526-SM-5EGJX
132QS-1226-SM-5P9GD
1399R-1626-SM-5P9GG
139TS-1726-SM-5IJG5
13FLW-2126-SM-5N9FD
13N2G-0126-SM-5N9DV
13NZB-2026-SM-5MR4M
13O61-2026-SM-5J2M6
13OVL-0426-SM-5IFG6
13OW8-0526-SM-5KM24
144GL-0726-SM-5LU4P
145LT-0426-SM-5LUAP
145MO-0126-SM-5S2QU
147GR-0626-SM-5S2PK
14A6H-2326-SM-5Q5B5
14BIL-2226-SM-73KWF
14C5O-2326-SM-73KYU
14E6E-1026-SM-664N9
14PJ2-2026-SM-6AJAQ
14PJN-1626-SM-68727
15RIF-1826-SM-6M469
16AAH-1626-SM-7EWE2
16YQH-1826-SM-6LPJW
17F9E-1626-SM-7EWDB

17GQL-1726-SM-718B8
17HII-0126-SM-7KFSS
17MFQ-0826-SM-793C8
18A66-0726-SM-72D77
18A7B-1526-SM-7KFTH
1A3MV-0726-SM-72D5M
1AX9I-1826-SM-72D5I
1AYCT-1026-SM-79ONR
1B8L1-2326-SM-9JGGA
1BAJH-0726-SM-7IGMF
1C64O-2126-SM-7IGPB
1CAMR-1526-SM-79OLP
1CB4I-0926-SM-7MKFY
1EH9U-2626-SM-7IGQN
1EN7A-2226-SM-7MXU6
1F6IF-0526-SM-7MKHD
1GF9W-2126-SM-7MXUX
1GMR3-1726-SM-9JGGQ
1GN2E-0126-SM-9OSW8
1GTWX-2226-SM-9JGHD
1H1DG-2726-SM-9JGI1
1H4P4-1926-SM-9WPOO
1HCVE-2826-SM-9WPPI
1HSKV-1826-SM-CNPPM
1HUB1-2026-SM-A96S8
1I1GU-0726-SM-ARU7H
1ICLY-2926-SM-C1YS5
1IKJJ-2126-SM-C1YQU
1IY9M-2526-SM-C1YQF
1JJ6O-0526-SM-AHZ3G
1JKYN-1026-SM-CGQG4
1JMQK-2726-SM-CNNPI
1K2DU-2226-SM-CXZJY
1KD4Q-2126-SM-EV7A6
1KXAM-1826-SM-D3LAF
1LBAC-1826-SM-D3L9X
1LSVX-2126-SM-EV7A9
1MA7X-1526-SM-DHXJF
1N2EE-0826-SM-E6CRI
1OKEX-1926-SM-E6CP7

17HGU-0726-SM-7DUFN
17KNJ-1126-SM-7KFT6
183FY-1926-SM-7KFRI
18A67-1826-SM-7KFT7
18D9B-2726-SM-72D73
1A3MX-1026-SM-731F8
1AX9J-1226-SM-72D6P
1B8KE-1426-SM-7EWEL
1B8SF-2926-SM-731DL
1C4CL-1926-SM-731DY
1C6VR-1526-SM-7MKG9
1CB4F-2126-SM-7MXUL
1E1VI-1026-SM-7MKGQ
1EKGG-2726-SM-79OOD
1EU9M-1626-SM-7EWF2
1F75A-2826-SM-7MXTS
1GL5R-0826-SM-9KNTS
1GMRU-0626-SM-7MKH2
1GN73-1726-SM-9JGFR
1GZ4I-2726-SM-9JGG9
1H1E6-0626-SM-9OSWF
1HB9E-1926-SM-D4P34
1HKZK-1926-SM-9WPPK
1HSMO-2426-SM-A9G24
1I1GP-2426-SM-B2LXK
1I1GV-2526-SM-B2LXL
1IDJF-2226-SM-AHZ2T
1IL2U-0126-SM-CNPQ5
1J1R8-1326-SM-CE6TC
1JJEA-1926-SM-AHZ41
1JMLX-0726-SM-AHZ3M
1JN6P-2826-SM-CXZJK
1KANA-1626-SM-CXZL2
1KD5A-1826-SM-DHXJI
1L5NE-1626-SM-DHXKW
1LG7Y-2326-SM-EVR56
1LVA9-2826-SM-EAZ5D
1MCQQ-2326-SM-DLHBX
1NHNU-1526-SM-E6CP2
1PDJ9-1426-SM-DPRYW
52

17HHE-1226-SM-793C6
17MF6-2726-SM-7IGMZ
18465-1526-SM-7KFTV
18A6Q-2626-SM-7KFT3
18QFQ-1926-SM-72D5H
1AX8Z-2826-SM-73KTZ
1AX9K-1826-SM-731CY
1B8KZ-1826-SM-73KVJ
1B996-2326-SM-731EC
1C64N-2826-SM-7IGP5
1C6VS-1126-SM-7EWEW
1CB4G-2426-SM-7DUGM
1E2YA-2826-SM-7EPIN
1EMGI-0626-SM-7MXUS
1F6I4-1426-SM-7MXU3
1GF9V-0626-SM-7MXU1
1GMR2-0726-SM-7MXVK
1GN1V-1826-SM-9JGGD
1GPI7-1426-SM-9JGGR
1H11D-1626-SM-9JGHM
1H1ZS-2826-SM-9OSXS
1HBPN-2226-SM-9WPNR
1HSEH-0726-SM-B2LXD
1HSMQ-1726-SM-B2LXZ
1I1GS-1826-SM-C1YS8
1I6K7-2426-SM-AHZ2I
1IDJH-2326-SM-D4P2K
1IOXB-1526-SM-A96T6
1J8Q3-0726-SM-AHZ3W
1JK1U-0726-SM-C1YPZ
1JMQJ-0726-SM-CXZJJ
1K2DA-1326-SM-CGQGP
1KANB-2126-SM-DHXJV
1KWVE-1126-SM-DHXJY
1LB8K-2326-SM-DHXJL
1LSNL-2426-SM-DHXKO
1M5QR-2626-SM-EV7AV
1MJK2-1326-SM-EV7A4
1O97I-2426-SM-DPRZ2
1PIGE-1626-SM-DPRZE

1PIIG-0526-SM-E6CQM
1QMI2-2826-SM-DPRXR
1QP6S-0826-SM-E6CPP
1R9K5-2326-SM-DPRZC
1RAZR-2226-SM-E6CRG
1S5VW-2626-SM-EVR4W
NFK9-0126-SM-3LK5H
OIZF-2126-SM-7P8R2
OIZI-0126-SM-3NB13
OXRL-2126-SM-3NM98
PVOW-2126-SM-EZ6LN
Q2AI-1226-SM-48U14
QLQW-1026-SM-447A9
QV44-1726-SM-4R1KG
R55E-0726-SM-48FCZ
RN64-2326-SM-48FDW
RWSA-2426-SM-47JXR
S4Q7-1226-SM-4AD5I
S7SE-0326-SM-4AT5Q
SNOS-1126-SM-4DM67
T6MN-2026-SM-4DM7L
U3ZH-1526-SM-4DXV1
U8T8-1126-SM-4DXUE
V1D1-2126-SM-4JBH4
WFON-2026-SM-4LVMW
WHSE-0426-SM-4M1XO
WQUQ-0326-SM-EWRM7
WYJK-1826-SM-4ONDM
X3Y1-2626-SM-4PQZI
XBEC-0126-SM-4GIDT
XK95-2726-SM-4V6G6
XPT6-1626-SM-4B655
Y111-2426-SM-4TT23
Y8E4-2226-SM-5LU94
YEC3-1726-SM-5IFIK
YFCO-1726-SM-4W21S
ZA64-1626-SM-5CVME
ZDYS-1326-SM-5IJFF
ZQUD-2026-SM-51MSM
ZTSS-1526-SM-51MTC

1PPGY-0726-SM-EXOJ7
1QP29-0426-SM-EVR3Y
1QP9N-1326-SM-DPRZN
1RAZA-2126-SM-EVR4A
1RB15-1926-SM-EV79J
1S831-2026-SM-EXOJP
O5YT-2126-SM-3MJGD
OIZG-0126-SM-E9TI2
OOBJ-2126-SM-3NB1N
P4QS-2126-SM-3NMCF
PW2O-1426-SM-48TCD
QEG4-0126-SM-48TZE
QMRM-1526-SM-4R1K6
R55C-1426-SM-48FED
REY6-0126-SM-48FDT
RUSQ-2126-SM-47JXK
S33H-0126-SM-4AD62
S4Z8-2126-SM-4AD5H
S95S-1126-SM-4B64E
SUCS-1326-SM-4DM5T
TKQ1-0926-SM-4DXU2
U3ZM-1626-SM-4DXSK
U8XE-0126-SM-4E3I3
VJYA-1426-SM-4KL1Y
WH7G-1926-SM-4LVMM
WK11-0326-SM-4OOS6
WVLH-2626-SM-4MVNV
WZTO-0326-SM-4PQYZ
X5EB-2026-SM-4E3KA
XBED-2026-SM-4AT5D
XLM4-1526-SM-4AT6D
XPVG-2226-SM-4B65U
Y3I4-2026-SM-4TT6Z
Y9LG-1726-SM-4VBQE
YEC4-1526-SM-4W1YU
YJ89-0626-SM-4TT3Z
ZAB4-0126-SM-5CVMG
ZLFU-2026-SM-4WWG2
ZT9W-2226-SM-57WFU
ZTX8-1126-SM-51MRM
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1QAET-1926-SM-DPRZG
1QP2A-1626-SM-E6CPO
1R7EU-1726-SM-DTX9M
1RAZQ-1126-SM-EAZ4S
1RQED-1626-SM-EAZ55
N7MS-0126-SM-3TW8O
OHPM-2126-SM-3LK75
OIZH-2126-SM-3NB1P
OOBK-2126-SM-3LK5T
PLZ6-1226-SM-3P5ZS
Q2AH-1526-SM-48TZG
QEG5-0126-SM-CMKFD
QV31-1126-SM-CKZNA
R55D-0126-SM-48FEL
RM2N-1326-SM-48FCW
RVPV-1126-SM-EAZAV
S3XE-1526-SM-4AD5A
S7PM-0626-SM-4AD4Q
SNMC-1026-SM-4DM7K
T5JC-0726-SM-4DM55
TKQ2-1526-SM-4DXUN
U4B1-1526-SM-4DXSL
UPJH-0126-SM-4IHLL
WFG8-1926-SM-4LVM1
WHSB-2126-SM-4M1XF
WOFM-1126-SM-4OOSB
WY7C-2226-SM-4ONCS
X261-2326-SM-4PQYU
XAJ8-1326-SM-47JYT
XGQ4-2026-SM-4AT6G
XMK1-2026-SM-4B65K
XQ3S-2726-SM-4BOP2
Y5V6-1726-SM-4VDSZ
YB5E-1926-SM-5IFIG
YF7O-2026-SM-4W1YE
Z93S-1726-SM-5HL8G
ZAB5-2426-SM-5CVMW
ZPU1-2126-SM-57WED
ZT9X-1426-SM-5DUX1
ZUA1-2726-SM-59HLJ

ZV7C-2026-SM-5NQ8F
ZYFC-0126-SM-5GIEH

ZVTK-0126-SM-57WDG
ZYT6-2726-SM-5GICP
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ZVZP-2226-SM-57WBF
ZZ64-1126-SM-5GZXY

B

Executed Code

B.1

Ubuntu command line for cell line sample preparation

#BJ_ctrl_SRR7613003_rep1, BJ_ctrl_SRR7613004_rep1, BJ_ctrl_SRR7613005_rep1
fastq-dump --split-files --origfmt SRR7613003 SRR7613004 SRR7613005
#Trim reads
fastp -i SRR7613003_1.fastq -o SRR7613003_1.fastp_trimmed.fq -j
SRR7513003.fastp_trimmed.json -h SRR7613003_1.fastp_trimmed.html
fastp -i SRR7613004_1.fastq -o SRR7613004_1.fastp_trimmed.fq -j
SRR7513004.fastp_trimmed.json -h SRR7613004_1.fastp_trimmed.html
fastp -i SRR7613005_1.fastq -o SRR7613005_1.fastp_trimmed.fq -j
SRR7513005.fastp_trimmed.json -h SRR7613005_1.fastp_trimmed.html
#Run fastqc on trimmed files
fastqc *.fq
#Perform alignment/mapping with STAR
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR7613003_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE117808_BJ_HFF_rep1_
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR7613004_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE117808_BJ_HFF_rep2_
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR7613005_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE117808_BJ_HFF_rep3_
#Run htseq-count to count mapped reads
htseq-count -f bam -r pos -s no
GSE117808_BJ_HFF_rep1_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE117808_BJ_HFF_rep1_htseq.txt
htseq-count -f bam -r pos -s no
GSE117808_BJ_HFF_rep2_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE117808_BJ_HFF_rep2_htseq.txt
htseq-count -f bam -r pos -s no
GSE117808_BJ_HFF_rep3_Aligned.sortedByCoord.out.bam
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/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE117808_BJ_HFF_rep3_htseq.txt
#SKOV3_ctrl_SRR9694244_rep1, SKOV3_ctrl_SRR9694245_rep1,
SKOV3_ctrl_SRR9694246_rep1
fastq-dump --split-files --origfmt SRR7613003 SRR7613004 SRR7613005
#Trim reads
fastp -i SRR9694244_1.fastq -o SRR9694244_1.fastp_trimmed.fq -j
SRR9694244.fastp_trimmed.json -h SRR9694244_1.fastp_trimmed.html
fastp -i SRR9694245_1.fastq -o SRR9694245_1.fastp_trimmed.fq -j
SRR9694245.fastp_trimmed.json -h SRR9694245_1.fastp_trimmed.html
fastp -i SRR9694246_1.fastq -o SRR9694246_1.fastp_trimmed.fq -j
SRR9694246.fastp_trimmed.json -h SRR9694246_1.fastp_trimmed.html
#Run fastqc on trimmed files
fastqc *.fq
#Perform alignment/mapping with STAR
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR9694244_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE134375_SKOV3_WT_rep1_
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR9694245_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE134375_SKOV3_WT_rep2_
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR9694246_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE134375_SKOV3_WT_rep3_
#Run htseq-count to count mapped reads
htseq-count -f bam -r pos -s no
GSE134375_SKOV3_WT_rep1_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE134375_SKOV3_WT_rep1_htseq.txt
htseq-count -f bam -r pos -s no
GSE134375_SKOV3_WT_rep2_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE134375_SKOV3_WT_rep2_htseq.txt
htseq-count -f bam -r pos -s no
GSE134375_SKOV3_WT_rep3_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE134375_SKOV3_WT_rep3_htseq.txt
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#OVCAR3_ctrl_SRR9694250_rep1, OVCAR3_ctrl_SRR9694251_rep1,
OVCAR3_ctrl_SRR9694252_rep1
fastq-dump --split-files --origfmt SRR7613003 SRR7613004 SRR7613005
#Trim reads
fastp -i SRR9694250_1.fastq -o SRR9694250_1.fastp_trimmed.fq -j
SRR9694250.fastp_trimmed.json -h SRR9694250_1.fastp_trimmed.html
fastp -i SRR9694251_1.fastq -o SRR9694251_1.fastp_trimmed.fq -j
SRR9694251.fastp_trimmed.json -h SRR9694251_1.fastp_trimmed.html
fastp -i SRR9694252_1.fastq -o SRR9694252_1.fastp_trimmed.fq -j
SRR9694252.fastp_trimmed.json -h SRR9694252_1.fastp_trimmed.html
#Run fastqc on trimmed files
fastqc *.fq
#Perform alignment/mapping with STAR
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR9694250_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE134375_OVCAR3_WT_rep1_
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR9694251_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE134375_OVCAR3_WT_rep2_
STAR --runThreadN 12 --genomeDir
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/STAR_Index/ --readFilesIn
SRR9694252_1.fastp_trimmed.fq --outSAMtype BAM SortedByCoordinate -outFileNamePrefix GSE134375_OVCAR3_WT_rep3_
#Run htseq-count to count mapped reads
htseq-count -f bam -r pos -s no
GSE134375_OVCAR3_WT_rep1_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE134375_OVCAR3_WT_rep1_htseq.txt
htseq-count -f bam -r pos -s no
GSE134375_OVCAR3_WT_rep2_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE134375_OVCAR3_WT_rep2_htseq.txt
htseq-count -f bam -r pos -s no
GSE134375_OVCAR3_WT_rep3_Aligned.sortedByCoord.out.bam
/mnt/d/Indexes/Homo_sapiens/Gencode_GRCh38.p13/gencode.v33.annotation.gtf >
GSE134375_OVCAR3_WT_rep3_htseq.txt
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B.2

R pipeline for cell line and CT gene analysis

## VERSION 3 UPDATE NOTICE
# 3/21/22
# Removed the code that couldn't write plots as csv
# Updated figure and plot colors to be more consistent and help with colorblindness
# Added MA and Volcano plots to part 2 and increased log2FoldChange to be >2 from
>1
#Install Packages
install.packages("tidyverse")
if (!require("BiocManager", quietly = TRUE))
install.packages("BiocManager")
BiocManager::install(version = "3.14")
BiocManager::install("DESeq2")
#Load Libraries
library(tidyverse)
library(DESeq2)
library(readr)
library(ggVennDiagram)
library(pheatmap)
#
# Part 1: Cell line comparison
# The following code compares the expression of HFF, OVCAR3, and SKOV3 cell lines
#
## Compare all three together
#Get current directory path, where cell line files are stored
directory <- getwd()
#Get names of cell line files
cell_line_Files <- grep("rep._htseq",list.files(directory),value=TRUE)
#Assign conditions based on order they appear in sampleFiles
cell_line_Condition <data.frame(condition=rep(c("BJ_HFF","OVCAR3","SKOV3"),each=3))
#Create sampleTable for DESeq input using sampleFiles and sampleCondition
cell_line_Table <- data.frame(sampleName = cell_line_Files,
fileName = cell_line_Files,
condition = cell_line_Condition)
#Set the condition column to be a factor
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cell_line_Table$condition <- factor(cell_line_Table$condition)
#Prep data for DESeq running using HTseq data
dds.Cell_Lines <- DESeqDataSetFromHTSeqCount(sampleTable = cell_line_Table,
directory = directory,
design=~condition)
#Run DESeq
ddsCL <- DESeq(dds.Cell_Lines)
#Create PCA plot of the cell line data
vsdCL <- vst(ddsCL)
plotPCA(vsdCL, intgroup = 'condition')
write.csv(plotPCA(vsdCL, intgroup = 'condition', returnData=T),
file="HFF_SKOV3_OVCAR3.PCA.csv")
# Create heatmap of cell lines
cell_line_ordered_counts <- order(rowMeans(counts(ddsCL,normalized=TRUE)),
decreasing=TRUE)
CL_ordered_counts_df <- as.data.frame(colData(ddsCL)[,c("condition","sizeFactor")])
CL_select <- subset(CL_ordered_counts_df,select=-c(sizeFactor))
pheatmap(assay(vsdCL)[cell_line_ordered_counts,], cluster_rows=FALSE,
show_rownames=FALSE, cluster_cols=FALSE, annotaton_col=CL_select)

## Compare HFF to SKOV3
# Get HFF file names
hffFiles <- grep(pattern="_BJ_HFF_rep",list.files(directory), value=T)
# Get SKOV3 file names
skov3Files <- grep(pattern="_SKOV3_WT",list.files(directory), value=T)
# Combine the two lists
hsFiles <- append(hffFiles, skov3Files)
# Create condition table
hsCondition <- data.frame(condition=rep(c("BJ_HFF","SKOV3"),each=3))
# Create table for DESeq2
hsTable <- data.frame(sampleName = hsFiles,
fileName = hsFiles,
condition = hsCondition)
#Prep for DESeq2
dds.hs <- DESeqDataSetFromHTSeqCount(sampleTable=hsTable,
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directory=directory,
design=~condition)
#Run DESeq2
ddsHS<- DESeq(dds.hs)
# Extract Results
hs.res <- results(ddsHS, contrast=c("condition","BJ_HFF","SKOV3"))
# Convert to data frame
hs.res.df <- as.data.frame(hs.res)
# Extract baseMean, log2FoldChange, padj columns
hs.res.df2 <- hs.res.df%>%select(baseMean,log2FoldChange,padj)
# Remove NA rows
hs.res.df2 <- na.omit(hs.res.df2)
# Add significance coloumn
hs.res.df.labeled <- hs.res.df2%>%mutate(significance=ifelse(padj<=0.05 &
log2FoldChange>=2, "BJ_HFF",
ifelse(padj<=0.05 & log2FoldChange<=-2,
"SKOV3",
"Non-significant")))
# Calculate median adjusted p-value by significance
hs.res.df.labeled%>%group_by(significance)%>%summarize(median(padj))
# Extract highly expressed SKOV3 rows
highSKOV.hs <- hs.res.df.labeled%>%filter(padj<=0.05 & log2FoldChange <= -2)
# Create Volcano plot
#Orange=HFF, Cyan=SKOV3
ggplot(hs.res.df.labeled) +
geom_point(aes(x=log2FoldChange, y=-log10(padj), colour=significance)) +
ggtitle("SKOV3 vs BJ/HFF line") +
xlab("log2 fold change") +
ylab("-log10 adjusted p-value") +
scale_colour_manual(values=c("orange", "grey", "darkcyan"))+
geom_hline(yintercept = 1.3, colour="#990000", linetype="dashed") +
geom_vline(xintercept = 2, colour="#990000", linetype="dashed") +
geom_vline(xintercept = -2, colour="#990000", linetype="dashed")+
theme_bw()
# Create MA plot
#Orange=HFF, Cyan=SKOV3
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ggplot(hs.res.df.labeled)+
geom_point(aes(x=baseMean, y=log2FoldChange, size=-log10(padj), color=log2FoldChange)) +
ggtitle("MA Plot: SKOV3 vs HFF")+
xlab("baseMean")+
ylab("log2FoldChange")+
theme_bw()+
scale_color_gradient(low="darkcyan", high="orange")
## Compare HFF to OVCAR3
# Get OVCAR3 file names
ovcar3Files <- grep(pattern="_OVCAR3_WT",list.files(directory), value=T)
# Combine the two lists
hoFiles <- append(hffFiles, ovcar3Files)
# Create condition table
hoCondition <- data.frame(condition=rep(c("BJ_HFF","OVCAR3"),each=3))
# Create table for DESeq2
hoTable <- data.frame(sampleName = hoFiles,
fileName = hoFiles,
condition = hoCondition)
#Prep for DESeq2
dds.ho <- DESeqDataSetFromHTSeqCount(sampleTable=hoTable,
directory=directory,
design=~condition)
#Run DESeq2
ddsHO<- DESeq(dds.ho)
# Extract Results
ho.res <- results(ddsHO, contrast=c("condition","BJ_HFF","OVCAR3"))
# Convert to data frame
ho.res.df <- as.data.frame(ho.res)
# Extract baseMean, log2FoldChange, padj columns
ho.res.df2 <- ho.res.df%>%select(baseMean,log2FoldChange,padj)
# Remove NA rows
ho.res.df2 <- na.omit(ho.res.df2)
# Add significance coloumn
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ho.res.df.labeled <- ho.res.df2%>%mutate(significance=ifelse(padj<=0.05 &
log2FoldChange>=2, "BJ_HFF",
ifelse(padj<=0.05 & log2FoldChange<=-2,
"OVCAR3",
"Non-significant")))
# Calculate median adjusted p-value by significance
ho.res.df.labeled%>%group_by(significance)%>%summarize(median(padj))
# Extract highly expressed OVCAR3 rows
highOVCAR.ho <- ho.res.df.labeled%>%filter(padj<=0.05 & log2FoldChange <= -2)
# Create Volcano plot
# Orange=HFF Violet=OVCAR
ggplot(ho.res.df.labeled) +
geom_point(aes(x=log2FoldChange, y=-log10(padj), colour=significance)) +
ggtitle("OVCAR3 line vs BJ/HFF line") +
xlab("log2 fold change") +
ylab("-log10 adjusted p-value") +
scale_colour_manual(values=c("orange", "grey", "darkviolet"))+
geom_hline(yintercept = 1.3, colour="#990000", linetype="dashed") +
geom_vline(xintercept = 2, colour="#990000", linetype="dashed") +
geom_vline(xintercept = -2, colour="#990000", linetype="dashed")+
theme_bw()
# Create MA plot
# Orange=HFF Violet=OVCAR
ggplot(ho.res.df.labeled)+
geom_point(aes(x=baseMean, y=log2FoldChange, size=-log10(padj), color=log2FoldChange)) +
ggtitle("MA Plot: OVCAR3 vs BJ/HFF")+
xlab("baseMean")+
ylab("log2FoldChange")+
theme_bw()+
scale_color_gradient(low="darkviolet", high="orange")
## Compare SKOV3 to OVCAR3
# Combine the two lists
soFiles <- append(skov3Files, ovcar3Files)
# Create condition table
soCondition <- data.frame(condition=rep(c("SKOV3","OVCAR3"),each=3))
# Create table for DESeq2
soTable <- data.frame(sampleName = soFiles,
fileName = soFiles,
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condition = soCondition)
#Prep for DESeq2
dds.so <- DESeqDataSetFromHTSeqCount(sampleTable=soTable,
directory=directory,
design=~condition)
#Run DESeq2
ddsSO<- DESeq(dds.so)
# Extract Results
so.res <- results(ddsSO, contrast=c("condition","SKOV3","OVCAR3"))
# Convert to data frame
so.res.df <- as.data.frame(so.res)
# Extract baseMean, log2FoldChange, padj columns
so.res.df2 <- so.res.df%>%select(baseMean,log2FoldChange,padj)
# Remove NA rows
so.res.df2 <- na.omit(so.res.df2)
# Add significance coloumn
so.res.df.labeled <- so.res.df2%>%mutate(significance=ifelse(padj<=0.05 &
log2FoldChange>=2, "SKOV3",
ifelse(padj<=0.05 & log2FoldChange<=-2,
"OVCAR3",
"Non-significant")))
# Calculate median adjusted p-value by significance
so.res.df.labeled%>%group_by(significance)%>%summarize(median(padj))
# Extract highly expressed OVCAR3 rows
highOVCAR.so <- so.res.df.labeled%>%filter(padj<=0.05 & log2FoldChange <= -2)
# Create Volcano plot
# cyan=SKOV Violet=OVCAR
ggplot(so.res.df.labeled) +
geom_point(aes(x=log2FoldChange, y=-log10(padj), colour=significance)) +
ggtitle("OVCAR3 line vs SKOV3 line") +
xlab("log2 fold change") +
ylab("-log10 adjusted p-value") +
scale_colour_manual(values=c("grey", "darkviolet", "darkcyan"))+
geom_hline(yintercept = 1.3, colour="#990000", linetype="dashed") +
geom_vline(xintercept = 2, colour="#990000", linetype="dashed") +
geom_vline(xintercept = -2, colour="#990000", linetype="dashed")+
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theme_bw()
# Create MA plot
# Cyan=SKOV, Vilet=OVCAR
ggplot(so.res.df.labeled)+
geom_point(aes(x=baseMean, y=log2FoldChange, size=-log10(padj), color=log2FoldChange)) +
ggtitle("MA Plot: OVCAR3 vs SKOV3")+
xlab("baseMean")+
ylab("log2FoldChange")+
theme_bw()+
scale_color_gradient(low="darkviolet", high="cyan3")
#
# Part 2: DESeq of Ovary and Testis
# The following part compares expression of normal ovarian tissue to cancerous
# ovarian tissue, and normal ovarian tissue to normal testis tissue
# Get necessary files
OVARY_GTEX <- list.files(pattern="OVARY_GTEX-")
OVARY_TCGA <- list.files(pattern="TCGA_OVARY_")
TESTIS_GTEX <- list.files(pattern="TESTIS_GTEX-")
#Combine GTEX data and create TCGA data
GTEXData <- c(OVARY_GTEX, TESTIS_GTEX)
TCGAData <- c(OVARY_TCGA)
# Pull in metadata
metaData <- read.csv('meta_file_v3.csv',header = TRUE)
# Searching metadata for the given tissue types
h <- c()
for(i in 1:length(GTEXData)){
h <- append(h, which(metaData$SampleName == GTEXData[i]))
}
sampGTEX <- metaData[h,]
j <- c()
for(i in 1:length(TCGAData)){
j <- append(j, which(metaData$SampleName == TCGAData[i]))
}
sampTCGA <- metaData[j,]
# Condense metadata sets
metaSamp <- rbind(sampTCGA, sampGTEX)
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## DESeq2 performed on the normal tissues
NormalTable <- data.frame(sampleName = sampGTEX$SampleName, fileName =
sampGTEX$SampleName, condition = sampGTEX$Condition, primary_diagnosis =
sampGTEX$primary_diagnosis, gender = sampGTEX$gender, stage =
sampGTEX$tumor_stage)
ddsNormal <- DESeqDataSetFromHTSeqCount(sampleTable = NormalTable, directory
= getwd(), design =~condition)
ddsN <- DESeq(ddsNormal)
metaSamp <- droplevels(metaSamp)
# Extract results
ddsN.res <- results(ddsN, contrast=c("condition", "Germline_M", "Germline_F"))
# Convert to data frame
ddsN.res.df <- as.data.frame(ddsN.res)
# Extract baseMean, log2FoldChange, padj columns
ddsN.res.df2 <- ddsN.res.df%>%select(baseMean,log2FoldChange,padj)
# Remove NA rows
ddsN.res.df2 <- na.omit(ddsN.res.df2)
# Add significance column
ddsN.res.df.labeled <- ddsN.res.df2%>%mutate(significance=ifelse(padj<=0.01 &
log2FoldChange>=2, "Testis",
ifelse(padj<=0.01 & log2FoldChange<=2,"Ovary",
"Non-significant")))
# Calculate median adjusted p-value by significance
ddsN.res.df.labeled%>%group_by(significance)%>%summarize(median(padj))
# Create Volcano plot
# Teal=Testis Orange=Ovary
ggplot(ddsN.res.df.labeled) +
geom_point(aes(x=log2FoldChange, y=-log10(padj), colour=significance)) +
ggtitle("Testis tissue vs Ovary tissue (normal)") +
xlab("log2 fold change") +
ylab("-log10 adjusted p-value") +
scale_colour_manual(values=c("grey", "orange", "darkcyan"))+
geom_hline(yintercept = 1.3, colour="#990000", linetype="dashed") +
geom_vline(xintercept = 2, colour="#990000", linetype="dashed") +
geom_vline(xintercept = -2, colour="#990000", linetype="dashed")+
theme_bw()
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# Create MA plot
# Teal=Testis Orange=Ovary
ggplot(ddsN.res.df.labeled)+
geom_point(aes(x=baseMean, y=log2FoldChange, size=-log10(padj), color=log2FoldChange)) +
ggtitle("MA Plot: Testis tissue vs Ovary tissue (normal)")+
xlab("baseMean")+
ylab("log2FoldChange")+
theme_bw()+
scale_color_gradient(low="darkcyan", high="orange")
#
# PCA plot of the DESeq2 of normal tissues
vsdN <- vst(ddsN)
plotPCA(vsdN, intgroup = 'condition') ##Export as PNG and PDF
write.csv(plotPCA(vsdN, intgroup = 'condition', returnData =
T),file="Ovary.normal.PCA.csv")
## DESeq2 performed on cancer tissues
CancerTable <- data.frame(sampleName = sampTCGA$SampleName, fileName =
sampTCGA$SampleName, condition = sampTCGA$Condition, primary_diagnosis =
sampTCGA$primary_diagnosis, gender = sampTCGA$gender, stage =
sampTCGA$tumor_stage)
ddsCancer <- DESeqDataSetFromHTSeqCount(sampleTable = CancerTable, directory =
getwd(), design = ~1)
ddsC <- DESeq(ddsCancer)
# PCA FOR CANCER DATA
vsdC <- vst(ddsC)
plotPCA(vsdC, intgroup = 'condition') ##Export as PNG and PDF
write.csv(plotPCA(vsdC, intgroup = 'condition', returnData =
T),file="Ovary.tumor.PCA.csv")
# Getting rid of extra decimals, letters on the end of gene names, and combining normal +
germline data sets with cancer data sets
Normal1 <- counts(ddsN, normalized = FALSE)
x <- row.names(Normal1)
x <- gsub("\\..*","",x)
row.names(Normal1) <- x
Cancer1 <- counts(ddsC, normalized = FALSE)
y <- row.names(Cancer1)
y <- gsub("\\..*","",y)
row.names(Cancer1) <- y
Merge <- merge(Cancer1, Normal1, by = "row.names")
66

write.csv(Merge, file="Ovary_unnormalized.csv")
# DESeq2 performed on cancer and normal data together
ddsMerge <- DESeqDataSetFromMatrix(countData = Merge, colData = metaSamp,
design = ~Condition, tidy = TRUE)
ddsM <- DESeq(ddsMerge)
write.csv(counts(ddsM, normalized=TRUE), file="Ovary_normalized.csv")
# Extract Results and convert to dataframe
ddsM.res <- results(ddsM, contrast = c("Condition","Tumor","Germline_F"))
ddsM.res.df <- as.data.frame(ddsM.res)
# Extract baseMean, log2FoldChange, padj columns
ddsM.res.df2 <- ddsM.res.df%>%select(baseMean,log2FoldChange,padj)
# Remove NA rows
ddsM.res.df2 <- na.omit(ddsM.res.df2)
# Add significance column
ddsM.res.df.labeled <- ddsM.res.df2%>%mutate(significance=ifelse(padj<=0.01 &
log2FoldChange>=2, "Tumor",
ifelse(padj<=0.01 & log2FoldChange<=2,"Ovary",
"Non-significant")))
# Calculate median adjusted p-value by significance
ddsM.res.df.labeled%>%group_by(significance)%>%summarize(median(padj))
# Create Volcano plot
# Purple=Tumor Orange=Ovary
ggplot(ddsM.res.df.labeled) +
geom_point(aes(x=log2FoldChange, y=-log10(padj), colour=significance)) +
ggtitle("Ovary tissue (cancer) vs Ovary tissue (normal)") +
xlab("log2 fold change") +
ylab("-log10 adjusted p-value") +
scale_colour_manual(values=c("grey", "orange", "darkviolet"))+
geom_hline(yintercept = 1.3, colour="#990000", linetype="dashed") +
geom_vline(xintercept = 2, colour="#990000", linetype="dashed") +
geom_vline(xintercept = -2, colour="#990000", linetype="dashed")+
theme_bw()
# Create MA plot
# Purple=Tumor Orange=Ovary
ggplot(ddsM.res.df.labeled)+
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geom_point(aes(x=baseMean, y=log2FoldChange, size=-log10(padj), color=log2FoldChange)) +
ggtitle("MA Plot: Ovary tissue (cancer) vs Ovary tissue (normal)")+
xlab("baseMean")+
ylab("log2FoldChange")+
theme_bw()+
scale_color_gradient(low="darkviolet", high="orange")
# PCA of merged data
vsd <- vst(ddsM, blind = FALSE)
plotPCA(vsd, intgroup = c("Condition"))
write.csv(plotPCA(vsd, intgroup = 'Condition', returnData = T),file="Ovary.PCA.csv")
# Extracting the gene list and number of genes
ddsM$Condition <- as.factor(ddsM$Condition)
ddsMerge$Condition <- as.factor(ddsMerge$Condition)
# Number of genes UP in testis VS normal (not cancers!!)
TvN <- results(ddsM, contrast = c('Condition', 'Germline_M', 'Germline_F'))
which1 <- which(TvN$padj < 0.01 & TvN$log2FoldChange > 2)
TvN_count <- length(which1)
write.csv(as.data.frame(TvN), file="Ovary_TestisvNormal2.csv")
# Number of genes UP in cancer VS normal
CvN <- results(ddsM, contrast = c('Condition', 'Tumor', 'Germline_F'))
which2 <- which(CvN$padj < 0.01 & CvN$log2FoldChange > 2)
CvN_count <- length(which2)
write.csv(as.data.frame(CvN), file="Ovary_TumorvNormal2.csv")
## Create vennDiagram
TvN_genes <- row.names(TvN[which1,])
CvN_genes <- row.names(CvN[which2,])
CT.venn <- list(A=TvN_genes,B=CvN_genes)
ggVennDiagram(CT.venn, category.names=c("Up in Testis", "Up in Cancer")) +
scale_fill_gradient(low="darkviolet", high="orange")
## Gene list for OVARY: Cancer+germlineTissue
geneNames <- CvN[intersect(which1, which2),]
genes <- row.names(geneNames)
write.table(genes, file = 'OVARY_genes_Cancer+germlineTissue2.txt', sep = ",",
row.names = FALSE)
## Generate heatmap
select <- order(rowMeans(counts(ddsM,normalized=TRUE)), decreasing=TRUE)
df <- as.data.frame(colData(ddsM)[,c("Condition","Tissue")])
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pheatmap(assay(vsd)[select,], cluster_rows=FALSE, show_rownames=FALSE,
cluster_cols=FALSE, annotation_col=df)
#
# Part 3: Compare CT genes to Cell Lines
# Using the genes found in part 2, run DESeq2 with the ovary cancer tissues on the
# HFF, OVCAR3, and SKOV3 tissues to get gene list with the following criteria:
# 1. Down regulated in HFF
# 2. Up regulated in SKOV3
# 3. Higher up regulation in OVCAR3
#
# v2 Update: gene are normalized so they can be compared to CT gene list
# Extract genes from the Cell Line lists
highOVCAR.ho.genes <- rownames(highOVCAR.ho)
highOVCAR.so.genes <- rownames(highOVCAR.so)
highSKOV.hs.genes <- rownames(highSKOV.hs)
# Normalize gene names to compare against CT gene list
highOVCAR.ho.genes.norm <- gsub("\\..*","",highOVCAR.ho.genes)
highOVCAR.so.genes.norm <- gsub("\\..*","",highOVCAR.so.genes)
highSKOV.hs.genes.norm <- gsub("\\..*","",highSKOV.hs.genes)
## Create vennDiagram of the Cell Line genes
#create list of number of genes in each comparison
CL.venn <list(A=highSKOV.hs.genes.norm,B=highOVCAR.ho.genes.norm,C=highOVCAR.so.gen
es.norm)
#plot vennDiagram
ggVennDiagram(CL.venn, category.names = c("SKOV3 > BJ/HFF","OVCAR3 >
BJ/HFF", "OVCAR3 > SKOV3"))+
scale_fill_gradient(low="orange",high="darkcyan")
# In order to get a list of genes meeting the criteria, the intersect of these three gene lists
is taken
patternGenes <- intersect(intersect(highSKOV.hs.genes.norm,
highOVCAR.ho.genes.norm), highOVCAR.so.genes.norm)
write.csv(patternGenes, "PatternGenes.csv")
# Check if any ovarian ct genes are in this set
checkGenes <- intersect(genes, patternGenes)
write.csv(checkGenes, "ResultsGenes.csv")
## Create vennDiagram of overlapping genes
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final.venn <- list(A=genes,B=patternGenes)
ggVennDiagram(final.venn,category.names = c("CT genes","Cell Line"))+
scale_fill_gradient(low="darkviolet", high="cyan4")

70

